<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id>
<journal-id journal-id-type="publisher-id">JCMM</journal-id>
<journal-title-group>
<journal-title>Journal of Cellular and Molecular Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1582-1838</issn>
<issn pub-type="epub">1582-4934</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27097531</article-id>
<article-id pub-id-type="pmc">4956943</article-id>
<article-id pub-id-type="doi">10.1111/jcmm.12839</article-id>
<article-id pub-id-type="publisher-id">JCMM12839</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>hi<styled-content style="fixed-case">PSC</styled-content>‐derived <styled-content style="fixed-case">iMSC</styled-content>s: NextGen <styled-content style="fixed-case">MSC</styled-content>s as an advanced therapeutically active cell resource for regenerative medicine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="jcmm12839-cr-0001">
<name>
<surname>Sabapathy</surname>
<given-names>Vikram</given-names>
</name>
<xref ref-type="aff" rid="jcmm12839-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="jcmm12839-cr-0002">
<name>
<surname>Kumar</surname>
<given-names>Sanjay</given-names>
</name>
<xref ref-type="aff" rid="jcmm12839-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="jcmm12839-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Center for Stem Cell Research</named-content>
<named-content content-type="organisation-division">A Unit of inStem Bengaluru</named-content>
<institution>Christian Medical College</institution>
<named-content content-type="city">Vellore</named-content>
<named-content content-type="street">Tamil Nadu</named-content>
<country country="IN">India</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence to: Sanjay KUMAR, Ph.D.<break></break>
E‐mail: <email>skumar@cmcvellore.ac.in</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2016</year>
</pub-date>
<volume>20</volume>
<issue>8</issue>
<issue-id pub-id-type="doi">10.1111/jcmm.2016.20.issue-8</issue-id>
<fpage>1571</fpage>
<lpage>1588</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:JCMM-20-1571.pdf" xlink:type="simple"></self-uri>
<abstract id="jcmm12839-abs-0001">
<title>Abstract</title>
<p>Mesenchymal stem cells (<styled-content style="fixed-case">MSC</styled-content>s) are being assessed for ameliorating the severity of graft‐versus‐host disease, autoimmune conditions, musculoskeletal injuries and cardiovascular diseases. While most of these clinical therapeutic applications require substantial cell quantities, the number of <styled-content style="fixed-case">MSC</styled-content>s that can be obtained initially from a single donor remains limited. The utility of <styled-content style="fixed-case">MSC</styled-content>s derived from human‐induced pluripotent stem cells (hi<styled-content style="fixed-case">PSC</styled-content>s) has been shown in recent pre‐clinical studies. Since adult <styled-content style="fixed-case">MSC</styled-content>s have limited capability regarding proliferation, the quantum of bioactive factor secretion and immunomodulation ability may be constrained. Hence, the alternate source of <styled-content style="fixed-case">MSC</styled-content>s is being considered to replace the commonly used adult tissue‐derived <styled-content style="fixed-case">MSC</styled-content>s. The <styled-content style="fixed-case">MSC</styled-content>s have been obtained from various adult and foetal tissues. The hi<styled-content style="fixed-case">PSC</styled-content>‐derived <styled-content style="fixed-case">MSC</styled-content>s (<styled-content style="fixed-case">iMSC</styled-content>s) are transpiring as an attractive source of <styled-content style="fixed-case">MSC</styled-content>s because during reprogramming process, cells undergo rejuvination, exhibiting better cellular vitality such as survival, proliferation and differentiations potentials. The autologous <styled-content style="fixed-case">iMSC</styled-content>s could be considered as an inexhaustible source of <styled-content style="fixed-case">MSC</styled-content>s that could be used to meet the unmet clinical needs. Human‐induced <styled-content style="fixed-case">PSC</styled-content>‐derived <styled-content style="fixed-case">MSC</styled-content>s are reported to be superior when compared to the adult <styled-content style="fixed-case">MSC</styled-content>s regarding cell proliferation, immunomodulation, cytokines profiles, microenvironment modulating exosomes and bioactive paracrine factors secretion. Strategies such as derivation and propagation of <styled-content style="fixed-case">iMSC</styled-content>s in chemically defined culture conditions and use of footprint‐free safer reprogramming strategies have contributed towards the development of clinically relevant cell types. In this review, the role of i<styled-content style="fixed-case">PSC</styled-content>‐derived mesenchymal stromal cells (<styled-content style="fixed-case">iMSC</styled-content>s) as an alternate source of therapeutically active <styled-content style="fixed-case">MSC</styled-content>s has been described. Additionally, we also describe the role of <styled-content style="fixed-case">iMSC</styled-content>s in regenerative medical applications, the necessary strategies, and the regulatory policies that have to be enforced to render iMSC's effectiveness in translational medicine.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="jcmm12839-kwd-0001">mesenchymal stem cells</kwd>
<kwd id="jcmm12839-kwd-0002"><styled-content style="fixed-case">MSC</styled-content>s</kwd>
<kwd id="jcmm12839-kwd-0003">induced pluripotent stem cells</kwd>
<kwd id="jcmm12839-kwd-0004">hi<styled-content style="fixed-case">PSC</styled-content>s</kwd>
<kwd id="jcmm12839-kwd-0005"><styled-content style="fixed-case">iMSC</styled-content>s</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>DBT</funding-source>
<award-id>BT/PR8527/MED/31/234/2013</award-id>
<award-id>BT/PR8742/AGR/36/773/2013</award-id>
<award-id>BT/PR15420/MED/31/122/2011</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="18"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>jcmm12839</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>August 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.2 mode:remove_FC converted:22.07.2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="jcmm12839-sec-0001" sec-type="opening-section">
<title>Introduction</title>
<p>Mesenchymal stromal cells (MSCs) are assorted cell preparations and only a rare subpopulation often referred to as ‘mesenchymal stem cells’ retains clonogenic proliferation ability &amp; multilineage differentiation potential <xref ref-type="ref" rid="jcmm12839-bib-0001">1</xref>. Mesenchymal stem cell preparations are significantly affected by starting cell source/material, such as bone marrow (BM), adipose tissue (AT) or other adult/perinatal tissue source; cell culture surface, media composition and other <italic>in vitro</italic> tissue culture conditions <xref ref-type="ref" rid="jcmm12839-bib-0001">1</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0002">2</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0009">9</xref>. Furthermore, they acquire phenotypic, biochemical, molecular as well as functional changes during long‐term <italic>in vitro</italic> culture expansion ending in replicative senescence <xref ref-type="ref" rid="jcmm12839-bib-0007">7</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0008">8</xref>. So far, MSCs are occasionally defined by their plastic adherent growth displaying fibroblast‐like cellular colonies, a panel of positive (CD73, CD90, CD105) and negative cell surface markers (CD11b/CD14, CD34, CD45, CD79α/CD19) for phenotypic characterization and their capacity to differentiate towards at least trilineage differentiations such as adipogenic, osteogenic and chondrogenic lineages <xref ref-type="ref" rid="jcmm12839-bib-0002">2</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0004">4</xref>. Many researchers indicate that plasticity and immunomodulatory capabilities of the MSCs contribute towards unique therapeutic potentials of the MSCs <xref ref-type="ref" rid="jcmm12839-bib-0001">1</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0002">2</xref>. The bone marrow MSCs (BMMSCs) are considered to be the gold standard in the field of MSCs. However, their invasive accessibility and lower proliferation potential significantly undermine their ability to be considered for mainstream therapeutic applications <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The therapeutic potency of MSCs is often limited because of age or pathologically related impairments regarding cell survival, proliferation and differentiations potential of BMMSCs <xref ref-type="ref" rid="jcmm12839-bib-0004">4</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0005">5</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0006">6</xref>. Before adult MSCs can exert its therapeutic potential <italic>in vivo</italic>; we must determine reasons behind their limited proliferation capability, quick down‐gradation of their differentiation potentials and secrete minimal protective factors during their expansion <italic>ex vivo</italic>? <xref ref-type="ref" rid="jcmm12839-bib-0007">7</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0008">8</xref> The adult MSCs unveil time‐limited functions under both <italic>in vivo</italic> and <italic>in vitro</italic> conditions <xref ref-type="ref" rid="jcmm12839-bib-0009">9</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0010">10</xref>. Exploration for an alternate source of MSCs resulted in several groups reporting successful isolation of MSCs like cells from foetal, neonatal <xref ref-type="ref" rid="jcmm12839-bib-0011">11</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0012">12</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0013">13</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0014">14</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0015">15</xref> and embryonic stem cells (ESCs) <xref ref-type="ref" rid="jcmm12839-bib-0016">16</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0017">17</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0018">18</xref>. As a result of the current deficit in adult MSCs regarding inadequacy in MSCs passages, cell numbers and consistencies in cellular behaviour; alternative, easily accessible, safe and healthy populations of MSCs are being considered for clinical applications <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The iPSC‐derived MSCs (iMSCs) are emerging as an attractive option for obtaining a substantial population of stem cells in a sustained manner for regenerative medical applications <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The achievement of cell‐based therapy of MSCs in preclinical trials has precipitated success in human translational applications <xref ref-type="ref" rid="jcmm12839-bib-0019">19</xref>.</p>
</sec>
<sec id="jcmm12839-sec-0003">
<title>Therapeutically active MSCs derived from human bone marrow</title>
<p>In the field of regenerative medicine, human mesenchymal stem cells (hMSCs) have transpired to be a promising candidate. Bone marrow‐derived MSCs (BMMSCs) have been used as a predominant source of MSCs. Bone marrow‐derived MSCs have been successfully used in a significant number of clinical and pre‐clinical applications <xref ref-type="ref" rid="jcmm12839-bib-0020">20</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0021">21</xref>. In the early 20th century, Maximow and Friedenstein were the first to investigate the role of bone marrow fibroblast‐like subset cells in maintaining the haematopoiesis <xref ref-type="ref" rid="jcmm12839-bib-0022">22</xref>. The BMMSCs were first isolated and propagated under <italic>in vitro</italic> culture conditions in 1970s by Friedenstein <italic>et al</italic>. <xref ref-type="ref" rid="jcmm12839-bib-0021">21</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0022">22</xref>. In 1991, Arnold Caplan termed the cells MSCs based on the ability of the cells to give rise to distinct tissue lineages <xref ref-type="ref" rid="jcmm12839-bib-0023">23</xref>. Maureen Owen further characterized the MSCs and observed the heterogeneity in its population <xref ref-type="ref" rid="jcmm12839-bib-0021">21</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0024">24</xref>. The <italic>in vivo</italic> administration of the MSCs in animal and humans has shown to be safe without triggering adverse immune reaction or any tumour formation <xref ref-type="ref" rid="jcmm12839-bib-0025">25</xref>. Subsequently, MSCs have been shown to modulate the immune response and prevent graft‐versus‐host disease (GVHD) <xref ref-type="ref" rid="jcmm12839-bib-0026">26</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0027">27</xref>. Above all MSCs has been demonstrated to be effective in both pre‐clinical and clinical stages in orthopaedic applications, cardiovascular therapies, burns, wounds, ulcers, neurodegenerative disorders, spinal cord injury, autoimmune disorders, <italic>etc</italic>., <xref ref-type="ref" rid="jcmm12839-bib-0028">28</xref>. Mesenchymal stem cells exert their biological functions through cellular migration, local engraftment, self‐renewal, plasticity, and secretion of various bioactive compounds. These intrinsic characteristics render the MSCs ideal for regenerative medical applications <xref ref-type="ref" rid="jcmm12839-bib-0029">29</xref>. Moreover, MSCs can be engineered to secrete various bioactive factors through viral or non‐viral‐based methods, which enhance the capabilities of MSCs in therapeutic applications <xref ref-type="ref" rid="jcmm12839-bib-0030">30</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0031">31</xref>. The low proliferation potential of the adult BMMSCs renders the BMMSCs unsuitable for clinical applications <xref ref-type="ref" rid="jcmm12839-bib-0032">32</xref>. Further, the limited accessibility, difficulty in obtaining patient consent and invasive procedure contribute towards un‐usability of BMMSCs for routine clinical treatment. During specific times extraction of autologous MSCs from the patients might be counter‐productive for the management of the patients <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The BMMSCs are short‐lived and hence cannot ensure consistent, long‐lasting immune regulatory functions both <italic>in vivo</italic> and <italic>in vitro</italic>
<xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Moreover, the adult MSCs undergoes replicative senescence at a very early stage of proliferative cycle rendering it disadvantageous to use the cells for transplantation <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. Hence, for mainstream therapeutic applications alternate source of MSCs must be considered.</p>
<p>In this regard, human‐induced pluripotent stem cells (hiPSCs) reprogrammed from human adult somatic cells, converge to a better‐defined ground state of pluripotency. Human‐induced pluripotent stem cells can be differentiated into all three germ layer cell types (Ectodermal, Mesodermal and Endodermal) of the organism and – while in the pluripotent state – can be cultured virtually indefinitely without significant signs of replicative senescence. A recent breakthrough in the generation of hiPSCs from human somatic cells by using defined factors, <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0035">35</xref> could facilitate generation of patient‐specific iMSCs derived from hiPSCs. The iMSCs have the capabilities for utilization in a broad range of regenerative medical applications. Hence, they are often considered as readily accessible promising source of stem cells for future clinical therapies <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The iMSCs shared the similar properties compared to the ESC‐derived MSCs <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Recent studies have also revealed that biomimetic surface results in the rapid and efficient derivation of iMSCs from hiPSCs <xref ref-type="ref" rid="jcmm12839-bib-0036">36</xref>. However, several challenges need to be effectively tackled before iMSCs could be favourably used for translational applications.</p>
</sec>
<sec id="jcmm12839-sec-0004">
<title>Human pluripotent stem cells (hESCs &amp; hiPSCs) as a novel cell resource for generating clinical‐grade products</title>
<p>The PSCs could serve as an alternate source for the generation of MSCs. Embryonic stem cells can be used as an efficient source to generate the MSCs almost indefinitely, attributed to tremendous proliferation potential of ESCs <xref ref-type="ref" rid="jcmm12839-bib-0037">37</xref>. Nonetheless, ethical concerns, allogenicity and immune reactivity proffer ESC‐derived MSCs unsuitable for clinical applications <xref ref-type="ref" rid="jcmm12839-bib-0030">30</xref>. On the other hand, efficient hiPSCs reprogramming methods could be successfully used to obtain patient‐specific iPSCs. Takahashi and Yamanaka were the first groups to demonstrate that mouse <xref ref-type="ref" rid="jcmm12839-bib-0032">32</xref> and human <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref> somatic cells could be successfully converted to iPSCs through the retroviral delivery of Oct4, Sox2, Klf4 and C‐Myc. Further characterization of iPSCs indicated human iPSCs are similar to human ESCs in their morphology, gene expression profile, <italic>in vitro</italic> differentiation potential and teratoma formation <xref ref-type="ref" rid="jcmm12839-bib-0030">30</xref>. Different types of human somatic cells have been successfully shown to reprogram into hiPSCs (Table <xref ref-type="table-wrap" rid="jcmm12839-tbl-0001">1</xref>).</p>
<table-wrap id="jcmm12839-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Different types of human somatic cells that have been reprogrammed to induced pluripotent stem cells (hiPSCs)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Cell source</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Bone marrow MSCs</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0038">38</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Adipose tissue‐derived stem cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0039">39</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cord blood cell</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0040">40</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Keratinocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0041">41</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Skin fibroblasts</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0041">41</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mammary epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0042">42</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Renal epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0043">43</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Corneal epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0044">44</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Peripheral blood cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0045">45</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Umbilical cord MSCs</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0046">46</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Placental MSCs</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0047">47</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Amniotic membrane MSCs</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0046">46</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Amniotic fluid‐derived cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0048">48</xref>
</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>The discovery of hiPSCs has accelerated the regenerative medical research <xref ref-type="ref" rid="jcmm12839-bib-0019">19</xref>. Human‐induced PSCs are cells that have the capability of differentiating into all somatic cell derivatives (all three germ layers, for example, ectoderm, mesoderm and endoderm) and also, make a contribution to the germline (Table <xref ref-type="table-wrap" rid="jcmm12839-tbl-0002">2</xref> shows a catalogue of different cell types derived from iPSCs); this unique ability of contribution to chimera and indefinite self‐renewal provides a unique opportunity for autologous personalized cell‐based therapy <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0049">49</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0050">50</xref>. Towards future studies, hiPSCs are considered as the driving force for personalized cell replacement therapy <xref ref-type="ref" rid="jcmm12839-bib-0051">51</xref>.</p>
<table-wrap id="jcmm12839-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>List of different cell types including iMSCs derived from hiPSCs</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Cell types</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="2" rowspan="1">Ectoderm</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Neural</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0052">52</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Retinal pigment epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0053">53</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Corneal epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0044">44</xref>
</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Mesoderm</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Cardiomyocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0054">54</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Adipocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0055">55</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Osteocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0056">56</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Chondrocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0057">57</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">iMSCs</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Haematopoietic stem cells (HSCs)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0059">59</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Erythrocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0060">60</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Platelets</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0061">61</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Endothelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0062">62</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Neutrophils</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0063">63</xref>
</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Endoderm</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Lung and airway epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0064">64</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Nephrogenic intermediates</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0065">65</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Follicular epithelial cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0066">66</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Hepatocytes</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0067">67</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Kidney progenitor cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0068">68</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0069">69</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Pancreatic beta cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0070">70</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Germ cells</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0071">71</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0072">72</xref>
</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="jcmm12839-sec-0005">
<title>Establishment of reliable and standardized source of functional MSCs for regenerative applications</title>
<p>The establishment of a reliable source of autologous, transgene‐free progenitor cells have enormous potential in the field of cell‐based regenerative medicine <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0004">4</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0030">30</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0035">35</xref>, for example, in preparing a therapeutic strategy for infants born with devastating birth defects <xref ref-type="ref" rid="jcmm12839-bib-0073">73</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0074">74</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0075">75</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0076">76</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0077">77</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0078">78</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0079">79</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0080">80</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0081">81</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0082">82</xref>. However, standardization of MSCs remains a major obstacle to the therapeutic usage in regenerative medicine <xref ref-type="ref" rid="jcmm12839-bib-0030">30</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0031">31</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0083">83</xref>. Comparison of experimental data with different studies becomes difficult when starting materials and culture conditions affects cell preparations <xref ref-type="ref" rid="jcmm12839-bib-0006">6</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0008">8</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0010">10</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0016">16</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0017">17</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0018">18</xref>.</p>
<p>Recent studies using RNA‐based technology <xref ref-type="ref" rid="jcmm12839-bib-0084">84</xref>, pluripotency‐associated protein transfection <xref ref-type="ref" rid="jcmm12839-bib-0085">85</xref>, non‐integrating methods of the pluripotent gene containing plasmid usage <xref ref-type="ref" rid="jcmm12839-bib-0086">86</xref> and a pluripotent gene containing Sendai viral vectors <xref ref-type="ref" rid="jcmm12839-bib-0087">87</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0088">88</xref> are hinting towards safe clinical usage of footprint‐free hiPSC‐derived cellular products, such as iMSCs, since these directed differentiated cells will not have any risk of undesired genomic modifications associated with reprogramming protocol.</p>
</sec>
<sec id="jcmm12839-sec-0006">
<title>iMSCs as a novel source of therapeutically active MSCs</title>
<p>The adult MSCs does not exhibit long‐lasting immunoregulatory functions <italic>in vitro</italic> and <italic>in vivo</italic>
<xref ref-type="ref" rid="jcmm12839-bib-0010">10</xref>. The primary source of MSCs with high‐proliferation potential has been reported as a suitable alternative to the adult MSCs sources <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. The development of hiPSCs has, in turn, led to the culmination of the unique ability to generate iMSCs by directed differentiation (Table <xref ref-type="table-wrap" rid="jcmm12839-tbl-0003">3</xref>). Recent data suggest that iMSCs are emerging as a strong contender for the new sources of MSCs that could be suitable to replace the adult MSCs. Particularly, of late many studies have reported successful derivation of functional MSCs from iPSCs (iMSCs) <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0036">36</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0050">50</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0089">89</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0090">90</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0091">91</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0092">92</xref>. The iMSCs are a novel class of stem cells that augments effective and reliable regeneration than contemporary methods. The iMSCs can be obtained from the readily accessible adult tissues and exhibit greater proliferation potential than the traditional sources of MSCs <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. Because of the promising pre‐clinical and clinical therapeutic potential of MSCs, the iMSCs derived from iPSCs may serve as an alternate and inexhaustible source <xref ref-type="ref" rid="jcmm12839-bib-0093">93</xref>. Additionally, the synthetic coating has been shown to assist in the derivation of iMSCs. The derivation of iPSCs into iMSCs on synthetic polymer coating, PMEDSAH [Poly [2‐(methacryloyloxy) ethyl dimethyl‐(3‐sulfopropyl) ammonium hydroxide] resulted in high differentiation efficiency, tri‐lineage differentiation potential and expression of characteristic MSCs markers (CD73<sup>+</sup>, CD90<sup>+</sup>, CD105<sup>+</sup>, CD166<sup>+</sup>, CD31<sup>−</sup>, CD34<sup>−</sup> and CD45<sup>−</sup>) <xref ref-type="ref" rid="jcmm12839-bib-0091">91</xref>. Similarly, Liu <italic>et al</italic>. has shown that iMSCs could be orderly derived in a single step from iPSCs on fibrillar collagen coating <xref ref-type="ref" rid="jcmm12839-bib-0036">36</xref>. In a recent study, Chen <italic>et al</italic>. has shown that treatment of iPSCs with SB431542, a transforming growth factor β pathway inhibitor to generate epithelial monolayer‐like cells in two‐dimensional (2D) culture system followed by induction of epithelial–mesenchymal transition lead to rapid and reliable differentiation into iMSCs <xref ref-type="ref" rid="jcmm12839-bib-0050">50</xref>. Overexpression of Oct4 along with the combination of GSK3 inhibitor has been demonstrated to reprogram CD34<sup>+</sup> peripheral blood or cord blood into functional mesenchymal stromal cells <xref ref-type="ref" rid="jcmm12839-bib-0094">94</xref>.</p>
<table-wrap id="jcmm12839-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Cell culture supplements that promote <italic>in vitro</italic> derivation of iMSCs from hiPSCs</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Materials/Additives</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Synthetic polymer, PMEDSAH</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0091">91</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fibrillar collagen</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0036">36</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SB431542, a TGF‐β pathway inhibitor</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0050">50</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">RGD (Arg‐Gly‐Asp) peptides</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0095">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fibronectin (Fn)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0095">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fibronectin‐like engineered polymer protein (FEPP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0095">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extracellular matrix, Geltrex</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0095">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Platelet concentrate</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0095">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Oct4</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0094">94</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CHIR99021, GSK inhibitor</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0094">94</xref>
</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="jcmm12839-sec-0007">
<title>Phenotypic features of iMSCs</title>
<p>The specific cell surface marker on the human MSCs remains to be properly elucidated. Currently, a panel of markers is used to characterize the MSCs isolated from different tissue sources, since there is no specific marker for identifying the bonafide MSCs. The iMSCs satisfies the essential criteria's such as plastic adherence, expression of key MSC surface markers and tri‐lineage differentiation capability properties as laid down by the International Society of Cellular Therapy <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. Himeno <italic>et al</italic>. have demonstrated that iMSCs from mice exhibited characteristic mice MSC surface marker such as CD105, CD140a, Sca‐1 and CD44 as previously described <xref ref-type="ref" rid="jcmm12839-bib-0019">19</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0096">96</xref>. The immunosuppressive, cytoprotection and tissue regeneration properties are exerted by the paracrine factors secreted by the MSCs <xref ref-type="ref" rid="jcmm12839-bib-0097">97</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0098">98</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0099">99</xref>. The iMSCs and ESC‐derived MSCs displayed attenuation of proliferation and cytolytic activity of NK cells in a similar way to BMMSCs. The iMSCs offer vast superiority than traditional sources of MSCs, as they can be generated from any tissue source from the body and theoretically iPSCs pose unlimited growth potential. Thus, iMSCs should serve as an inexhaustible source of MSCs <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The human MSCs from various tissue sources are typically identified by the expression CD29, CD44, CD73, CD90, CD105, CD146 and CD166. Newer studies have reported that human iMSCs exhibited the above indicated typical characteristics of adult MSCs <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>.</p>
</sec>
<sec id="jcmm12839-sec-0008">
<title>Biological characteristics of iMSCs:</title>
<p>The iMSCs and ESC‐derived MSCs displayed similar strong immunosuppressive characteristics <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>, also iMSCs display a wide range of cytokine profiles, microenvironment modulatory paracrine factors and exert different functions on the local cellular niche components <italic>via</italic> secretion of suitable bioactive molecules (Fig. <xref ref-type="fig" rid="jcmm12839-fig-0001">1</xref>). Giuliani <italic>et al</italic>. further reported that there was no marked functional variability between iMSCs and ESCs–MSCs <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Unlike BMMSCs, iMSCs and ESCs–MSCs that could be subjected to long‐term culture without resulting in explicative senescence <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Studies by Lian <italic>et al</italic>. have shown that iMSCs display typical MSC characteristics and there were no differences between human iMSCs and human ESC‐derived MSCs <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0083">83</xref>. More robust proliferation was observed in iMSCs than BMMSCs. The iMSCs could be easily scaled up to more than 40 passages while stably maintaining normal diploid karyotype, and consistent gene expression and surface antigen profile <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. Human iMSCs apart from typical MSCs characteristic markers such as CD29, CD44 and CD73 also expressed a higher level of endogenous pluripotency markers such as Oct4 <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. Liu has proposed that iMSCs derived from blood cells could be used as a novel and patient‐specific source for usage in disc repair <xref ref-type="ref" rid="jcmm12839-bib-0100">100</xref>. Comparative study of DNA methylation profiles of iMSCs with normal MSCs and PSCs suggested that iMSCs maintained donor‐derived epigenetic differences <xref ref-type="ref" rid="jcmm12839-bib-0101">101</xref>. In a recent study, published by Frobel <italic>et al</italic>. iMSCs are starter MSCs and subjected to epigenetic analysis. The study indicated that morphology, immunophenotype, <italic>in vitro</italic> differentiation and gene expression of iMSCs were consistent with the initial donor MSCs population. Except iMSCs were impaired in suppressing T‐cell proliferation. The iMSCs retained donor‐derived DNA methylation (DNAm) profile. However, tissue‐specific and age‐related DNAm profiles of iMSCs were completely erased. Further, the iMSCs reacquired senescence‐associated DNAm. The study also contrastingly highlights that iMSCs reacquire incomplete immunomodulatory functions <xref ref-type="ref" rid="jcmm12839-bib-0102">102</xref>.</p>
<fig fig-type="Figure" id="jcmm12839-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Intrinsic features of <styled-content style="fixed-case">iMSC</styled-content>s, which may allow them to have better biological effectiveness compared to adult <styled-content style="fixed-case">hMSC</styled-content>s. Multilineage differentiations may obtain a variety of specialized cells for cell replacement therapy (Table <xref ref-type="table-wrap" rid="jcmm12839-tbl-0002">2</xref> lists different types of cells obtained from hi<styled-content style="fixed-case">PSC</styled-content>s). Various cytokines in their secretome profile also help immunomodulation, antifibrotic, anti‐apoptotic activities. The microenvironment modulatory paracrine factors may exert a wide range of cellular functions on local cellular niche components <italic>via</italic> the release of the suitable bioactive compound.</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="JCMM-20-1571-g001"></graphic>
</fig>
</sec>
<sec id="jcmm12839-sec-0009">
<title>Directed Differentiation of iMSCs</title>
<p>The use of stem cells and biologically suitable scaffolds offer the full potential for tissue regeneration. Transplantation of lineage‐committed cells can obviate <italic>in vivo</italic> teratoma formation that is caused by the rapid proliferation and uncontrolled spontaneous differentiation of PSCs. Thus, controlled differentiation of hiPSCs into cells that resemble adult MSCs is an attractive approach to obtain a readily available source of progenitor cells for tissue engineering. Unlike previously reported methods that typically rely on the addition of soluble factors to affect PSC differentiation, a recent study by Liu <italic>et al</italic>. reports an alternative approach using a biomaterial coating on a cell culture plate made of fibrillar collagen Type I to promote the derivation of MSC‐like cells. This study has reported a collagen matrix that could potentially play a positive role in regulating the differentiation of hESCs and hiPSCs towards a multipotent mesenchymal progenitor cell <xref ref-type="ref" rid="jcmm12839-bib-0036">36</xref>. Activation of epithelial‐to‐mesenchymal transition (EMT) of epithelial cells has been used successfully by others for generation of MSC‐like cells from hESCs <xref ref-type="ref" rid="jcmm12839-bib-0103">103</xref>. A study by ThienHan <italic>et al</italic>. to generate MSCs from human iPSCs, and investigate the osteogenic differentiation of iMSCs seeded on biofunctionalized CPCs containing RGD (Arg‐Gly‐Asp) peptides, fibronectin (Fn), Fibronectin‐like engineered polymer protein (FEPP), Geltrex and platelet concentrate has also been reported <xref ref-type="ref" rid="jcmm12839-bib-0080">80</xref>. A significant part of the study dedicated to the investigation of iMSCs proliferation and osteogenic differentiation atop calcium phosphate cement (CPC) containing biofunctional agents was also evaluated <xref ref-type="ref" rid="jcmm12839-bib-0080">80</xref>.</p>
</sec>
<sec id="jcmm12839-sec-0010">
<title>Therapeutic applications of iMSCs</title>
<p>The iMSCs could be effectively used for diseases modelling, drug screening and therapeutic applications (Fig. <xref ref-type="fig" rid="jcmm12839-fig-0001">1</xref>). The immunological concerns on cell therapy can be effectively bypassed by iMSCs <xref ref-type="ref" rid="jcmm12839-bib-0051">51</xref>. Nevertheless, the long‐term studies on the immunosuppressive activity of the iMSCs remain to be explored <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Mesenchymal stem cells are considered as the first line of prophylactic treatment for GVHD and organ transplantation owing to their immunoregulatory properties <xref ref-type="ref" rid="jcmm12839-bib-0027">27</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0104">104</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0105">105</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0106">106</xref>. During allogeneic transplantation, the circulating NK cells target and destroy the graft <xref ref-type="ref" rid="jcmm12839-bib-0107">107</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0108">108</xref>. On the other hand cotransplantation of MSCs prevent GVHD by attenuating the cytotoxic activity of NK Cells <xref ref-type="ref" rid="jcmm12839-bib-0027">27</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0105">105</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0106">106</xref>. Under <italic>in vitro</italic> culture conditions Giuliani <italic>et al</italic>. has shown that human MSCs derived from the iPSCs considerably down‐regulated NK cell cytolytic capabilities <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. The iMSCs were more potent than the BMMSCs. Thus, iMSCs can be graded as a useful therapeutic option to prevent allograft rejection <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. The study from Himeno <italic>et al</italic>. showed MSCs from iPSCs ameliorated diabetic polyneuropathy (DNP) in mice <xref ref-type="ref" rid="jcmm12839-bib-0019">19</xref>. The results suggest that effects of DNP by MSCs might be because of the secretion of angiogenic/neurotrophic factors and differentiation into Schwann type cells. Mesenchymal stem cells have also been reportedly considered as a potential treatment option for periodontal defects arising from periodontitis. A report by Hynes <italic>et al</italic>. indicated that iMSCs facilitated the periodontal regeneration coupled with newly formed mineralized tissue in periodontitis rat models <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. Recently, Yang <italic>et al</italic>. demonstrated that tumour necrosis factor alpha‐stimulated gene‐6 (TSG6) expressing iMSCs were capable of decreasing the inflammation in experimental periodontitis model and inhibiting alveolar bone resorption <xref ref-type="ref" rid="jcmm12839-bib-0109">109</xref>. Human MSCs have emerged as a promising therapeutic source for treating myocardial and limb ischaemia <xref ref-type="ref" rid="jcmm12839-bib-0110">110</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0111">111</xref>. An investigation by Lian <italic>et al</italic>. revealed that human iMSCs attenuate limb ischaemia in mice <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. Further analysis showed that transplantation of iMSCs into mice exhibited better attenuation in hindlimb ischaemia than adult BM‐MSCs. The greater therapeutic efficacy can be attributed to their ability to survive for a longer time after transplantation. Tracking of transplanted iMSCs divulged, iMSCs could engraft and survive for more than 5 weeks following transplantation <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. Wei <italic>et al</italic>. indicated human iMSCs could continuously proliferate for more than 32 passages without undergoing cellular senescence and displayed superior wound healing and pro‐angiogenic properties <xref ref-type="ref" rid="jcmm12839-bib-0092">92</xref>. The iMSCs derived on a synthetic polymeric coating; PMEDSAH resulted in novel bone formation when transplanted into the mice with calvarial defects <xref ref-type="ref" rid="jcmm12839-bib-0091">91</xref>. Zang <italic>et al</italic>. have shown that iMSCs derived from Hutchinson–Gilford Progeria syndrome (HGPS) were helpful in studying the molecular pathology of HGPS <xref ref-type="ref" rid="jcmm12839-bib-0089">89</xref>. In a recent study, Liu <italic>et al</italic>. has successfully utilized iMSCs for modelling Fanconi anaemia. The Fanconi anaemia iPSC‐derived MSCs displayed premature senescence <xref ref-type="ref" rid="jcmm12839-bib-0112">112</xref>. Also, hiPSC‐derived cells have been successfully used to model various other diseases. We have provided the comprehensive details below in Table <xref ref-type="table-wrap" rid="jcmm12839-tbl-0004">4</xref>, a list of disease modelling using hiPSCs (Fig. <xref ref-type="fig" rid="jcmm12839-fig-0002">2</xref>).</p>
<table-wrap id="jcmm12839-tbl-0004" orientation="portrait" position="float" xml:lang="en">
<label>Table 4</label>
<caption>
<p>Disease modelling using hiPSCs</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="2" rowspan="1" valign="top">Disease modelling</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="3" rowspan="1">Neurological</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Development</td>
<td align="left" colspan="1" rowspan="1">Fragile X/ataxia syndrome (FXA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0074">74</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0113">113</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Rett syndrome (RS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0075">75</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Angleman syndrome</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0076">76</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Prader–Willi syndrome</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0076">76</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Timothy syndrome (TS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0077">77</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Microcephaly (MC)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0078">78</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hereditary spastic paraplegias (HSP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0079">79</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Olivopontocerebellar atrophy (OPCA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0080">80</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Pelizaeus–Merzbacher disorder (PMD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0081">81</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Mitochondrial encephalopathy with lactic acidosis and stroke‐like episodes (MELAS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0082">82</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glioblastoma iPSCs</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0114">114</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Childhood cerebral adrenoleukodystrophy (CCALD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0115">115</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Multiple sclerosis</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0116">116</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Autism spectrum disorder (ASD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0117">117</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Cernunnos deficiency syndrome (XLF)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0118">118</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">William–Beuren syndrome (WBS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0119">119</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">William–Beuren region duplication syndrome (WBDS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0119">119</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Degenerative</td>
<td align="left" colspan="1" rowspan="1">Alzheimer's (AD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0120">120</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0121">121</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0122">122</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Schizophrenia (SCZD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0123">123</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Spinal muscular atrophy (SMA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0124">124</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Parkinson disease (PD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0126">126</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0127">127</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Huntington disease (HD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0128">128</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Amyotrophic lateral sclerosis (ALS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0129">129</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Familial dysautonomia (FD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0130">130</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">X‐linked adrenoleukodystrophy (X‐ALD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0131">131</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Machado–Joseph disease (MJD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0132">132</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Friedreich's Ataxia (FRDA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0133">133</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Familial transthyretin amyloidosis (ATTR)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0134">134</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Tauopathies (TAP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0135">135</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Diabetic polyneuropathy (DPN)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0019">19</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Gaint axonal neuropathy (GAN)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0136">136</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Menkes disease (MD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0137">137</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Frontotemporal dementia (FTD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0138">138</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0139">139</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Spinal cerebral ataxia type2 (SCA2)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0140">140</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Ataxia telangiectasia (AT)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0141">141</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Dravet syndrome (DVS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0142">142</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hematological</td>
<td align="left" colspan="1" rowspan="1">Swachman–Bodian–Diamond syndrome (SBD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Adenosine deaminase deficiency (ADA) severe combined immunodeficiency (SCID)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fanconi anemia (FA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0143">143</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sickle cell anaemia (SCA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0144">144</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Beta‐thalassaemia (BT)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0145">145</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Polycythaemia vera (PV)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0146">146</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Congenital amegakaryocytic thrombocytopenia (CAMT)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0147">147</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Paroxysmal nocturnal haemoglobinuria (PNH)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0148">148</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Dyskeratosis congenita (DC)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0149">149</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">α‐Thalassaemia (AT)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0150">150</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Aplastic anaemia (AA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0151">151</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Myeloproliferative disorder (MPN)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0152">152</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Chronic myeloid leukaemia (CML)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0153">153</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Juveline myelomonocytic leukaemia (JMML)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0154">154</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Chronic infantile neurological, cutaneous and articular syndrome (CINCA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0155">155</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">X‐linked chronic granulomatous disease (X‐CGD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0156">156</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Severe congenital neutropaenia (SCN)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0157">157</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Wiskott–Aldrich syndrome (WAS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0158">158</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Metabolic</td>
<td align="left" colspan="1" rowspan="1">Gaucher disease type III (GD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Juvenile diabetes mellitus (JDM)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Lesch–Nyhan syndrome (LNS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Aplha1‐Antitrypsin deficiency (A1ATD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0159">159</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Pompe disease (PomD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0160">160</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Familial hypercholesterolaemia (FH)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0161">161</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Tyrosinaemia (TYS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0162">162</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycogen storage disease type1 (GSD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0162">162</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Progressive familial cholestasis (PFD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0162">162</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Crigler–Najjar syndrome (CN)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0162">162</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hurler syndrome (HS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0163">163</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Neuronal ceroid lipofuscinosis (NCL)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0164">164</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Wilson's disease (WD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0165">165</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Mitochondrial diabetes (MT)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0166">166</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fabry disease (FD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0087">87</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Mucopolysaccharidosis type IIIB disease (MPS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0167">167</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cardiovascular</td>
<td align="left" colspan="1" rowspan="1">LEOPARD syndrome (LS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0078">78</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Long QT syndrome type 1 (LQTS1)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0168">168</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Long QT syndrome type 2 (LQTS2)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0169">169</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Long QT syndrome type 3 (LQTS3)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0170">170</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Supervascular aortic stenosis (SVAS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0171">171</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hypertrophic cardiomyopathy (HCM)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0172">172</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Diabetic cardiomyopathy (DCM)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0173">173</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hypoplastic left heart syndrome (HLHS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0174">174</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Moyamoya disease (MMD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0175">175</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Catecholaminergic polymorphic ventricular tachycardia (CPVT)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0176">176</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Familial dilated cardiomyopathy (DCM)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0177">177</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Familial hypertrophic cardiomyopathy (HCM)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0178">178</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Primary immunodeficiency</td>
<td align="left" colspan="1" rowspan="1">SCID/Leaky SCID</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0179">179</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Omenn syndrome (OS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0179">179</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Cartilage–hair hypoplasia (CHH)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0179">179</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Herpes simplex encephalitis (HSE)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0179">179</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Musculoskeletal disorder</td>
<td align="left" colspan="1" rowspan="1">Craniometaphyseal dysplasia (CMD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0088">88</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Duchenne muscular dystrophy (DMD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Becker muscular dystrophy (BMD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Osteogenesis imperfect (OI)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0180">180</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Thanatophoric dysplasia (THD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0181">181</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Achondroplasia (ACH)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0181">181</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hutchinson–Gilford progeria syndrome (HGPS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0182">182</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Werner syndrome (WS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0183">183</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Facioscapulohumeral muscular dystrophy (FSHD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0184">184</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Limb‐girdle muscular dystrophy (LGMD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0185">185</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Myotonic dystrophy type 1 (MyD1)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0186">186</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Marfan syndrome (MFS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0187">187</xref>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fibrodysplsia ossificans progressiva (FOP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0188">188</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lung disorder</td>
<td align="left" colspan="1" rowspan="1">Cystic fibrosis (CF)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0189">189</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Pulmonary alveolar proteinosis (PAP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0190">190</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Emphysema (EP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0191">191</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dermatological Disorder</td>
<td align="left" colspan="1" rowspan="1">Recessive dystrophic epidermolysis bullosa (RDEB)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0192">192</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0193">193</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Scleroderma (SC)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0191">191</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Focal dermal hypoplasia (FDH)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0194">194</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Hermansky–Pudlak syndrome (HPS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0195">195</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Chediak–Higashi syndrome (CHS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0195">195</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cancer</td>
<td align="left" colspan="1" rowspan="1">Breast cancer (BC)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0196">196</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Opthalmological disorder</td>
<td align="left" colspan="1" rowspan="1">Retinitis pigmentosa (RP)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0053">53</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0197">197</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0198">198</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Gyrate atrophy (GA)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0199">199</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Best disease (BD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0200">200</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Cataract (Cat)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0201">201</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Ectrodactyly‐ectodermal dysplasia‐cleft syndrome (EEC)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0202">202</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nephrology</td>
<td align="left" colspan="1" rowspan="1">End stage renal disease (ESRD)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0203">203</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aneuploidy</td>
<td align="left" colspan="1" rowspan="1">Turner syndrome (TS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0204">204</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Warkany syndrome (WKS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0204">204</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Patau syndrome (PS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0204">204</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Emanuel syndrome (ES)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0204">204</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Klinefelter's syndrome (KS)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0205">205</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Down's syndrome</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="jcmm12839-bib-0125">125</xref>
</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<fig fig-type="Figure" id="jcmm12839-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Potential application overview of <styled-content style="fixed-case">iMSC</styled-content>s derived from hi<styled-content style="fixed-case">PSC</styled-content>s.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="JCMM-20-1571-g002"></graphic>
</fig>
</sec>
<sec id="jcmm12839-sec-0011">
<title>Recent developments in safe clinical products</title>
<sec id="jcmm12839-sec-0012">
<title>Challenges &amp; strategy to overcome them for Clinically Relevant iMSCs</title>
<p>Safety and Efficacy of iMSCs are of paramount importance to succeed in the field of translational regenerative medicine. The viral vector‐based strategy for reprogramming might result in tumour formation as a result of insertional mutagenesis of the transgene. C‐Myc is a proto‐oncogene that has been shown to increase the efficiency of reprogramming by suppressing the tumour suppressor p‐53 gene. The overexpression of proto‐oncogene and moderating of tumour suppressor genes render hiPSCs beneficial results regarding higher proliferative advantage for downstream translational applications <xref ref-type="ref" rid="jcmm12839-bib-0206">206</xref>. Consequently, many studies have unveiled several different strategies for generation of safer iPSCs. In 2010, Yamanaka's group suggested using L‐Myc as an alternative to C‐Myc for reprogramming based on the result that L‐Myc maintained in the reprogramming efficiency without inducing any tumorigenesis <xref ref-type="ref" rid="jcmm12839-bib-0206">206</xref>. Fang <italic>et al</italic>., reported generated iPSCs devoid of C‐Myc enervated retinal ischaemia and reperfusion injury following transplantation in rat models <xref ref-type="ref" rid="jcmm12839-bib-0207">207</xref>. The starter cell type has an enormous impact on reprogramming, differentiation and <italic>in vivo</italic> functionality because of epigenetic memory. Until now, there are no data on the best starter cell type for a particular clinical application. Hence, more research needs to be conducted to determine suitable starter cell type based on the type of clinical application <xref ref-type="ref" rid="jcmm12839-bib-0030">30</xref>. While iPSC‐derived cell source are emerging as a replacement cell source, their traits of self‐renewal and pluripotency after <italic>in vivo</italic> transplantation often leads to tumorigenicity and genomic instability might result in low clinical utility <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The nature of pluripotency transgene elements present in the iMSCs is arduous to predict. Hence, iMSCs have been thoroughly characterized for silencing of the transgene expression and safe transgene integration <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Presently, only initial studies are reported on preclinical applications of iMSCs. Hence, long‐term, multicentric, pre‐clinical and clinical studies are required for accurate prediction of iMSCs for the translational purpose <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. The recent development of non‐viral‐based generation of iPSCs might pave the way for considering iPSCs as a suitable candidate for biotherapeutics <xref ref-type="ref" rid="jcmm12839-bib-0086">86</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0208">208</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0209">209</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0210">210</xref>. Newer technologies without viral transgene such as chemicals, plasmids and recombinant protein‐based approaches might augment the clinical utilization of these safe iPSCs <xref ref-type="ref" rid="jcmm12839-bib-0085">85</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0211">211</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0212">212</xref>. The low efficiency of iPSCs generation might be a serve‐debilitating factor to consider iPSCs/iMSCs for translational applications. Hence, more research needs to be focused on scaling and optimizing the quality of iPSCs <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>.</p>
</sec>
<sec id="jcmm12839-sec-0013">
<title>Regulatory issues for future safe therapies using hiPSCs</title>
<p>The iPSCs present unique sets of technical and regulatory hurdles when compared to even ESCs for translational applications <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>. The issues regarding the cell and gene therapy in every country are governed by its sovereign regulatory body. In the United States, the human iPSC products are regulated by Centre for Biologics Evaluation and Research at the United States Food and Drug Administration (USFDA) <xref ref-type="ref" rid="jcmm12839-bib-0214">214</xref>. Before proceeding with the clinical trials, the iPSC‐derived products are subjected to preclinical testing that requires extensive examination of safety, feasibility and efficacy <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. Pre‐clinical studies involve a comparative analysis of the various parameters between healthy animals and disease models. According to the FDA guidelines, the same cells used in preclinical trials should be used during clinical trials <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. Small animal models, such as rodents are used in preclinical studies. However, rodent models, although could be used for basic biological studies have a poor predictive outcome in term of clinical efficacy <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. Consequently, pre‐clinical studies consisting of large animal models such as swine, primates, <italic>etc</italic>., are favourable as they have relatively longer life span and displays physiological similarities to humans albeit a limited number of disease models and inability to modify the genome with ease constitute major road block in the usage of large animal models <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. For a particular disease condition, a single satisfactory model is not present. Hence, pre‐clinical testing must be carried out using suitable alternative models to highlight potential limitations and assist in finding suitable alternative avenues for handling the disorder <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. Necessary precautions must be undertaken before extrapolating the results from animal models to clinical trials <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>.</p>
<p>Efficacy of the transplanted cells <italic>in vivo</italic> is not well documented. A few studies have demonstrated that transplantation of PSCs and differentiated cells resulted in poor survival of the cells <xref ref-type="ref" rid="jcmm12839-bib-0216">216</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0217">217</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0218">218</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0219">219</xref>. The fate of the transplanted cells must be evaluated to ascertain the tangible effectiveness of the cells <italic>in vivo</italic> following transplantation. Hence, suitable surgical/imaging techniques should be developed for <italic>in vivo</italic> fate mapping of the cells <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>.</p>
<p>Current good manufacturing protocol guidelines must be followed to generate and characterize iPSC‐based products <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref> for any future clinical applications. The quality of cell products and homogeneity of the cell population will determine the effect, risk and potency of the iPSC‐based therapy <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. Method and duration of storage, viability, cell line contamination and risks of transmissible infections are some of the other possible confounding factors that can affect the cell therapy <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>. Before scaling up towards clinical trials questions such as ideal cell source, efficient reprogramming and differentiation protocols, demonstration of safety and functionality have to be addressed <xref ref-type="ref" rid="jcmm12839-bib-0215">215</xref>.</p>
<p>Generation of iPSCs from somatic cells requires a significant amount of molecular manipulations <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref> either by viral vectors containing reprogramming genes <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref> or transfection of reprogramming mRNAs <xref ref-type="ref" rid="jcmm12839-bib-0084">84</xref> or purified reprogramming factors <xref ref-type="ref" rid="jcmm12839-bib-0085">85</xref> or transfection by non‐viral vectors containing reprogramming gene methods <xref ref-type="ref" rid="jcmm12839-bib-0086">86</xref>. The viral‐based reprogramming strategies form the basis of added concerns because of random integration into the host genome <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref>. On the contrary use of retroviral‐based genetically modified cells is technically permitted for human clinical trials under the existing National Institutes of Health (NIH), guidelines <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>. Recent strategies for using small molecule‐based reprogramming &amp; differentiation must be explored to develop and differentiate into clinical relevant cell types <xref ref-type="ref" rid="jcmm12839-bib-0220">220</xref>. Generation of iPSCs require a significant amount of manipulations <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>. The viral‐based reprogramming strategies form the basis of added concerns because of random integration into the host genome <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref>. On the contrary, use of retroviral‐based genetically modified cells is technically permitted for human clinical trials under the existing NIH, guidelines <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>. Recent strategies for using small molecule‐based reprogramming &amp; differentiation must be explored to develop and differentiate into clinical relevant cell types <xref ref-type="ref" rid="jcmm12839-bib-0220">220</xref>. Every iPSC line would exhibit unique genetic and epigenetic constitution. Hence, each and every cell line has to be subjected to independent characterization to determine its precise characteristic features <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>. It is necessary to determine to what extent iPSCs are similar to ESCs. Besides safety, efficacy, stability, heritability and absence of biased lineage differentiation have to examine and documented <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>.</p>
<p>Immune response against transplanted cells presents a critical challenge that can detrimentally affect the outcome of therapy. Some of the important questions as to why the donor cells pose a risk of immune response or genetic diseases, cell efficiency, cells exhibiting risk of contamination, effectiveness and safety of transplanted cells has to be answered, if they are perceived to develop into potential therapeutic agents <xref ref-type="ref" rid="jcmm12839-bib-0221">221</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0222">222</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0223">223</xref>. Tumour formation remains one of the most important concerns while using the pluripotent cells or PSC‐derived products. It has been well documented that the reminiscent PSCs present in differentiated cells could effectively give rise to tumour formation <xref ref-type="ref" rid="jcmm12839-bib-0217">217</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0219">219</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0224">224</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0225">225</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0226">226</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0227">227</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0228">228</xref>.</p>
<p>One of the biggest advantages of iPSCs is the possibility of generation of patient‐specific autologous cell lines. Hence, the cumbersome procedure of screening against different cell lines for a proper match is excluded <xref ref-type="ref" rid="jcmm12839-bib-0034">34</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>, <xref ref-type="ref" rid="jcmm12839-bib-0229">229</xref>. The method of selection and characterization criteria needs good manufacturing protocol <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>. The combination of a proven gene therapy with proven PSC‐derived products might hold a great potential for therapeutic application albeit certain technical and regulatory hurdles. Hence, suitable regulatory guidelines should be established for the application of genetically modified stem cells <xref ref-type="ref" rid="jcmm12839-bib-0213">213</xref>.</p>
</sec>
</sec>
<sec id="jcmm12839-sec-0014">
<title>Conclusion</title>
<p>The invention of cellular reprogramming of adult cells from the terminally differentiated state of PSCs state with the help of transcription factors, biological factors and small molecules open up a large window of opportunity in the field of regenerative medicine. By incorporating the advantages of both iPSCs and MSCs, the resulting iMSCs are emerging as a novel stem cell population <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. The iMSCs generated from iPSCs successfully exhibited all the fundamental criteria for defining the MSC population based on the existing knowledge <xref ref-type="ref" rid="jcmm12839-bib-0003">3</xref>. Data indicate that iMSCs can be used as a promising alternative strategy for treatment of various immune‐mediated diseases <xref ref-type="ref" rid="jcmm12839-bib-0033">33</xref>. Although, the concept of iMSCs is at its nascent stage, recent studies nevertheless provide the proof of concept that functional iMSCs could be successfully generated from iPSCs that exhibit robust proliferation and differentiation potential, which could be used for tissue repair and engineering applications <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. The development of iMSCs offers promise of patient‐specific, cost‐efficient and batch to batch consistency <xref ref-type="ref" rid="jcmm12839-bib-0058">58</xref>. Presently, the scope of iMSCs is limited to the pre‐clinical utility for tissue engineering‐based treatment approaches. Further pre‐clinical and clinical studies are required before scaling it towards routine clinical utility.</p>
</sec>
<sec id="jcmm12839-sec-0016">
<title>Conflicts of interest</title>
<p>None.</p>
</sec>
</body>
<back>
<ack id="jcmm12839-sec-0015">
<title>Acknowledgements</title>
<p>Dr. Kumar contributed to the conception, design, data collection, assembly, analysis, interpretation, manuscript writing and final approval of the manuscript. Vikram Sabapathy contributed to the data collection, analysis, manuscript writing and final approval of the manuscript. We would like to thank Department of Biotechnology (DBT), India for Ramalingaswami Fellowship and research support grant (DBT Grant nos’. BT/PR8527/MED/31/234/2013, BT/PR8742/AGR/36/773/2013 and BT/PR15420/MED/31/122/2011) to Sanjay Kumar.</p>
</ack>
<ref-list content-type="cited-references" id="jcmm12839-bibl-0001">
<title>References</title>
<ref id="jcmm12839-bib-0001">
<label>1</label>
<mixed-citation id="jcmm12839-cit-0001" publication-type="journal">
<string-name>
<surname>English</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>KJ</given-names>
</string-name>. <article-title>Mesenchymal stromal cells: facilitators of successful transplantation?</article-title>
<source/>Cell Stem Cell. <year>2010</year>; <volume>7</volume>: <fpage>431</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">20887949</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0002">
<label>2</label>
<mixed-citation id="jcmm12839-cit-0002" publication-type="journal">
<string-name>
<surname>Sabapathy</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Sundaram</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Vm</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human Wharton's Jelly Mesenchymal Stem Cells plasticity augments scar‐free skin wound healing with hair growth</article-title>. <source/>PLoS ONE. <year>2014</year>; <volume>9</volume>: <fpage>e93726</fpage>.<pub-id pub-id-type="pmid">24736473</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0003">
<label>3</label>
<mixed-citation id="jcmm12839-cit-0003" publication-type="journal">
<string-name>
<surname>Hynes</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Menicanin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells from iPS cells facilitate periodontal regeneration</article-title>. <source/>J Dent Res. <year>2013</year>; <volume>92</volume>: <fpage>833</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23884555</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0004">
<label>4</label>
<mixed-citation id="jcmm12839-cit-0004" publication-type="journal">
<string-name>
<surname>Roobrouck</surname>
<given-names>VD</given-names>
</string-name>, <string-name>
<surname>Ulloa‐Montoya</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Verfaillie</surname>
<given-names>CM</given-names>
</string-name>. <article-title>Self‐renewal and differentiation capacity of young and aged stem cells</article-title>. <source/>Exp Cell Res. <year>2008</year>; <volume>314</volume>: <fpage>1937</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">18439579</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0005">
<label>5</label>
<mixed-citation id="jcmm12839-cit-0005" publication-type="journal">
<string-name>
<surname>Xin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Aging adversely impacts biological properties of human bone marrow‐derived mesenchymal stem cells: implications for tissue engineering heart valve construction</article-title>. <source/>Artif Organs. <year>2010</year>; <volume>34</volume>: <fpage>215</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">19392880</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0006">
<label>6</label>
<mixed-citation id="jcmm12839-cit-0006" publication-type="journal">
<string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lehmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Honold</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease</article-title>. <source/>Circulation. <year>2004</year>; <volume>109</volume>: <fpage>1615</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">15037527</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0007">
<label>7</label>
<mixed-citation id="jcmm12839-cit-0007" publication-type="journal">
<string-name>
<surname>Kretlow</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>Y‐Q</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Donor age and cell passage affects differentiation potential of murine bone marrow‐derived stem cells</article-title>. <source/>BMC Cell Biol. <year>2008</year>; <volume>9</volume>: <fpage>60</fpage>.<pub-id pub-id-type="pmid">18957087</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0008">
<label>8</label>
<mixed-citation id="jcmm12839-cit-0008" publication-type="journal">
<string-name>
<surname>Wagner</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bork</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Horn</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>Aging and replicative senescence have related effects on human stem and progenitor cells</article-title>. <source/>PLoS ONE. <year>2009</year>; <volume>4</volume>: <fpage>e5846</fpage>.<pub-id pub-id-type="pmid">19513108</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0009">
<label>9</label>
<mixed-citation id="jcmm12839-cit-0009" publication-type="journal">
<string-name>
<surname>Pittenger</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Mackay</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Beck</surname>
<given-names>SC</given-names>
</string-name>, <italic>et al</italic>
<article-title>Multilineage potential of adult human mesenchymal stem cells</article-title>. <source/>Science. <year>1999</year>; <volume>284</volume>: <fpage>143</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">10102814</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0010">
<label>10</label>
<mixed-citation id="jcmm12839-cit-0010" publication-type="journal">
<string-name>
<surname>Uccelli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Moretta</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pistoia</surname>
<given-names>V</given-names>
</string-name>. <article-title>Mesenchymal stem cells in health and disease</article-title>. <source/>Nat Rev Immunol. <year>2008</year>; <volume>8</volume>: <fpage>726</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">19172693</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0011">
<label>11</label>
<mixed-citation id="jcmm12839-cit-0011" publication-type="journal">
<string-name>
<surname>Campagnoli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Identification of mesenchymal stem/progenitor cells in human first‐trimester fetal blood, liver, and bone marrow</article-title>. <source/>Blood. <year>2001</year>; <volume>98</volume>: <fpage>2396</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">11588036</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0012">
<label>12</label>
<mixed-citation id="jcmm12839-cit-0012" publication-type="journal">
<string-name>
<surname>Götherström</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ringdén</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Westgren</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Immunomodulatory effects of human foetal liver‐derived mesenchymal stem cells</article-title>. <source/>Bone Marrow Transplant. <year>2003</year>; <volume>32</volume>: <fpage>265</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">12858197</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0013">
<label>13</label>
<mixed-citation id="jcmm12839-cit-0013" publication-type="journal">
<string-name>
<surname>In ‘t Anker</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Noort</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Scherjon</surname>
<given-names>SA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells in human second‐trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential</article-title>. <source/>Haematologica. <year>2003</year>; <volume>88</volume>: <fpage>845</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">12935972</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0014">
<label>14</label>
<mixed-citation id="jcmm12839-cit-0014" publication-type="journal">
<string-name>
<surname>In ‘t Anker</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Scherjon</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Kleijburg‐van der Keur</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta</article-title>. <source/>Stem Cells. <year>2004</year>; <volume>22</volume>: <fpage>1338</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">15579651</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0015">
<label>15</label>
<mixed-citation id="jcmm12839-cit-0015" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>WY</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>HL</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation</article-title>. <source/>Cell Res. <year>2005</year>; <volume>15</volume>: <fpage>539</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">16045817</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0016">
<label>16</label>
<mixed-citation id="jcmm12839-cit-0016" publication-type="journal">
<string-name>
<surname>Barberi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Willis</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Socci</surname>
<given-names>ND</given-names>
</string-name>, <italic>et al</italic>
<article-title>Derivation of multipotent mesenchymal precursors from human embryonic stem cells</article-title>. <source/>PLoS Med. <year>2005</year>; <volume>2</volume>: <fpage>e161</fpage>.<pub-id pub-id-type="pmid">15971941</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0017">
<label>17</label>
<mixed-citation id="jcmm12839-cit-0017" publication-type="journal">
<string-name>
<surname>Choo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Derivation of mesenchymal stem cells from human embryonic stem cells</article-title>. <source/>Methods Mol Biol. <year>2011</year>; <volume>690</volume>: <fpage>175</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">21042993</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0018">
<label>18</label>
<mixed-citation id="jcmm12839-cit-0018" publication-type="journal">
<string-name>
<surname>Olivier</surname>
<given-names>EN</given-names>
</string-name>, <string-name>
<surname>Rybicki</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Bouhassira</surname>
<given-names>EE</given-names>
</string-name>. <article-title>Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells</article-title>. <source/>Stem Cells. <year>2006</year>; <volume>24</volume>: <fpage>1914</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">16644919</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0019">
<label>19</label>
<mixed-citation id="jcmm12839-cit-0019" publication-type="journal">
<string-name>
<surname>Himeno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kamiya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Naruse</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cell‐like cells derived from mouse induced pluripotent stem cells ameliorate diabetic polyneuropathy in mice</article-title>. <source/>Biomed Res. Int. <year>2013</year>; <volume>2013</volume>: <fpage>259187</fpage>.<pub-id pub-id-type="pmid">24319678</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0020">
<label>20</label>
<mixed-citation id="jcmm12839-cit-0020" publication-type="journal">
<string-name>
<surname>Pacini</surname>
<given-names>S</given-names>
</string-name>. <article-title>Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs)</article-title>. <source/>Front. Cell Dev. Biol. <year>2014</year>; <volume>2</volume>: <fpage>50</fpage>.<pub-id pub-id-type="pmid">25364757</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0021">
<label>21</label>
<mixed-citation id="jcmm12839-cit-0021" publication-type="journal">
<string-name>
<surname>Parekkadan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Milwid</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Mesenchymal stem cells as therapeutics</article-title>. <source/>Annu Rev Biomed Eng. <year>2010</year>; <volume>12</volume>: <fpage>87</fpage>–<lpage>117</lpage>.<pub-id pub-id-type="pmid">20415588</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0022">
<label>22</label>
<mixed-citation id="jcmm12839-cit-0022" publication-type="journal">
<string-name>
<surname>Friedenstein</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Chailakhyan</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Latsinik</surname>
<given-names>NV</given-names>
</string-name>, <italic>et al</italic>
<article-title>Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning <italic>in vitro</italic> and retransplantation <italic>in vivo</italic>
</article-title>. <source/>Transplantation. <year>1974</year>; <volume>17</volume>: <fpage>331</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">4150881</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0023">
<label>23</label>
<mixed-citation id="jcmm12839-cit-0023" publication-type="journal">
<string-name>
<surname>Caplan</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Mesenchymal stem cells</article-title>. <source/>J Orthop Res. <year>1991</year>; <volume>9</volume>: <fpage>641</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">1870029</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0024">
<label>24</label>
<mixed-citation id="jcmm12839-cit-0024" publication-type="journal">
<string-name>
<surname>Owen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Marrow stromal stem cells</article-title>. <source/>J Cell Sci Suppl. <year>1988</year>; <volume>10</volume>: <fpage>63</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">3077943</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0025">
<label>25</label>
<mixed-citation id="jcmm12839-cit-0025" publication-type="journal">
<string-name>
<surname>Bauer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dao</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Case</surname>
<given-names>SS</given-names>
</string-name>, <italic>et al</italic>
<article-title>
<italic>In vivo</italic> biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors</article-title>. <source/>Mol Ther. <year>2008</year>; <volume>16</volume>: <fpage>1308</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">18461052</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0026">
<label>26</label>
<mixed-citation id="jcmm12839-cit-0026" publication-type="journal">
<string-name>
<surname>Aggarwal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pittenger</surname>
<given-names>MF</given-names>
</string-name>. <article-title>Human mesenchymal stem cells modulate allogeneic immune cell responses</article-title>. <source/>Blood. <year>2005</year>; <volume>105</volume>: <fpage>1815</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">15494428</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0027">
<label>27</label>
<mixed-citation id="jcmm12839-cit-0027" publication-type="journal">
<string-name>
<surname>Le Blanc</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Frassoni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ball</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells for treatment of steroid‐resistant, severe, acute graft‐versus‐host disease: a phase II study</article-title>. <source/>Lancet. <year>2008</year>; <volume>371</volume>: <fpage>1579</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">18468541</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0028">
<label>28</label>
<mixed-citation id="jcmm12839-cit-0028" publication-type="journal">
<string-name>
<surname>Murphy</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Moncivais</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Caplan</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine</article-title>. <source/>Exp Mol Med. <year>2013</year>; <volume>45</volume>: <fpage>e54</fpage>.<pub-id pub-id-type="pmid">24232253</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0029">
<label>29</label>
<mixed-citation id="jcmm12839-cit-0029" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Qu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Clinical applications of mesenchymal stem cells</article-title>. <source/>J. Hematol. Oncol. <year>2012</year>; <volume>5</volume>: <fpage>19</fpage>.<pub-id pub-id-type="pmid">22546280</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0030">
<label>30</label>
<mixed-citation id="jcmm12839-cit-0030" publication-type="journal">
<string-name>
<surname>Jung</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Nolta</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Concise review: induced pluripotent stem cell‐derived mesenchymal stem cells: progress toward safe clinical products</article-title>. <source/>Stem Cells. <year>2012</year>; <volume>30</volume>: <fpage>42</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">21898694</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0031">
<label>31</label>
<mixed-citation id="jcmm12839-cit-0031" publication-type="journal">
<string-name>
<surname>Meyerrose</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Olson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pontow</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells for the sustained <italic>in vivo</italic> delivery of bioactive factors</article-title>. <source/>Adv Drug Deliv Rev. <year>2010</year>; <volume>62</volume>: <fpage>1167</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">20920540</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0032">
<label>32</label>
<mixed-citation id="jcmm12839-cit-0032" publication-type="journal">
<string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</string-name>. <article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title>. <source/>Cell. <year>2006</year>; <volume>126</volume>: <fpage>663</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">16904174</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0033">
<label>33</label>
<mixed-citation id="jcmm12839-cit-0033" publication-type="journal">
<string-name>
<surname>Giuliani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Oudrhiri</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Noman</surname>
<given-names>ZM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human mesenchymal stem cells derived from induced pluripotent stem cells down‐regulate NK‐cell cytolytic machinery</article-title>. <source/>Blood. <year>2011</year>; <volume>118</volume>: <fpage>3254</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">21803852</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0034">
<label>34</label>
<mixed-citation id="jcmm12839-cit-0034" publication-type="journal">
<string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tanabe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ohnuki</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>. <source/>Cell. <year>2007</year>; <volume>131</volume>: <fpage>861</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">18035408</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0035">
<label>35</label>
<mixed-citation id="jcmm12839-cit-0035" publication-type="journal">
<string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vodyanik</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Smuga‐Otto</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell lines derived from human somatic cells</article-title>. <source/>Science. <year>2007</year>; <volume>318</volume>: <fpage>1917</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">18029452</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0036">
<label>36</label>
<mixed-citation id="jcmm12839-cit-0036" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Dennis</surname>
<given-names>JE</given-names>
</string-name>, <italic>et al</italic>
<article-title>One‐step derivation of mesenchymal stem cell (MSC)‐like cells from human pluripotent stem cells on a fibrillar collagen coating</article-title>. <source/>PLoS ONE. <year>2012</year>; <volume>7</volume>: <fpage>e33225</fpage>.<pub-id pub-id-type="pmid">22457746</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0037">
<label>37</label>
<mixed-citation id="jcmm12839-cit-0037" publication-type="journal">
<string-name>
<surname>Thomson</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Itskovitz‐Eldor</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shapiro</surname>
<given-names>SS</given-names>
</string-name>, <italic>et al</italic>
<article-title>Embryonic stem cell lines derived from human blastocysts</article-title>. <source/>Science. <year>1998</year>; <volume>282</volume>: <fpage>1145</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">9804556</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0038">
<label>38</label>
<mixed-citation id="jcmm12839-cit-0038" publication-type="journal">
<string-name>
<surname>Zhao</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Gregory</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>RH</given-names>
</string-name>, <italic>et al</italic>
<article-title>MSCs derived from iPSCs with a modified protocol are tumor‐tropic but have much less potential to promote tumors than bone marrow MSCs</article-title>. <source/>Proc Natl Acad Sci USA. <year>2015</year>; <volume>112</volume>: <fpage>530</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">25548183</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0039">
<label>39</label>
<mixed-citation id="jcmm12839-cit-0039" publication-type="journal">
<string-name>
<surname>Aoki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohnishi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Oda</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of induced pluripotent stem cells from human adipose‐derived stem cells without c‐MYC</article-title>. <source/>Tissue Eng Part A. <year>2010</year>; <volume>16</volume>: <fpage>2197</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">20146561</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0040">
<label>40</label>
<mixed-citation id="jcmm12839-cit-0040" publication-type="journal">
<string-name>
<surname>Meng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Neises</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>R‐J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficient reprogramming of human cord blood CD34<sup>+</sup> cells into induced pluripotent stem cells with OCT4 and SOX2 alone</article-title>. <source/>Mol Ther. <year>2012</year>; <volume>20</volume>: <fpage>408</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">22108860</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0041">
<label>41</label>
<mixed-citation id="jcmm12839-cit-0041" publication-type="journal">
<string-name>
<surname>Streckfuss‐Bömeke</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Azizian</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Comparative study of human‐induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts</article-title>. <source/>Eur Heart J. <year>2013</year>; <volume>34</volume>: <fpage>2618</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">22798560</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0042">
<label>42</label>
<mixed-citation id="jcmm12839-cit-0042" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Enhancing mammary differentiation by overcoming lineage‐specific epigenetic modification and signature gene expression of fibroblast‐derived iPSCs</article-title>. <source/>Cell Death Dis. <year>2014</year>; <volume>5</volume>: <fpage>e1550</fpage>.<pub-id pub-id-type="pmid">25476898</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0043">
<label>43</label>
<mixed-citation id="jcmm12839-cit-0043" publication-type="journal">
<string-name>
<surname>Zhou</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Benda</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dunzinger</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of human induced pluripotent stem cells from urine samples</article-title>. <source/>Nat Protoc. <year>2012</year>; <volume>7</volume>: <fpage>2080</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23138349</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0044">
<label>44</label>
<mixed-citation id="jcmm12839-cit-0044" publication-type="journal">
<string-name>
<surname>Mikhailova</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ilmarinen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Uusitalo</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Small‐molecule induction promotes corneal epithelial cell differentiation from human induced pluripotent stem cells</article-title>. <source/>Stem Cell Reports. <year>2014</year>; <volume>2</volume>: <fpage>219</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">24527395</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0045">
<label>45</label>
<mixed-citation id="jcmm12839-cit-0045" publication-type="journal">
<string-name>
<surname>Sommer</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Rozelle</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector</article-title>. <source/>J Vis Exp. <year>2012</year>; <volume>68</volume>: <fpage>e4327</fpage>.</mixed-citation>
</ref>
<ref id="jcmm12839-bib-0046">
<label>46</label>
<mixed-citation id="jcmm12839-cit-0046" publication-type="journal">
<string-name>
<surname>Cai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells</article-title>. <source/>J Biol Chem. <year>2010</year>; <volume>285</volume>: <fpage>11227</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">20139068</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0047">
<label>47</label>
<mixed-citation id="jcmm12839-cit-0047" publication-type="journal">
<string-name>
<surname>Jiang</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Di Bernardo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Delong</surname>
<given-names>CJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells from human placental chorion for perinatal tissue engineering applications</article-title>. <source/>Tissue Eng Part C Methods. <year>2014</year>; <volume>20</volume>: <fpage>731</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">24447109</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0048">
<label>48</label>
<mixed-citation id="jcmm12839-cit-0048" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Pluripotency can be rapidly and efficiently induced in human amniotic fluid‐derived cells</article-title>. <source/>Hum Mol Genet. <year>2009</year>; <volume>18</volume>: <fpage>4340</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">19679563</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0049">
<label>49</label>
<mixed-citation id="jcmm12839-cit-0049" publication-type="journal">
<string-name>
<surname>Awaya</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Selective development of myogenic mesenchymal cells from human embryonic and induced pluripotent stem cells</article-title>. <source/>PLoS ONE. <year>2012</year>; <volume>7</volume>: <fpage>e51638</fpage>.<pub-id pub-id-type="pmid">23236522</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0050">
<label>50</label>
<mixed-citation id="jcmm12839-cit-0050" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Pelekanos</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ellis</surname>
<given-names>RL</given-names>
</string-name>, <italic>et al</italic>
<article-title>Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells</article-title>. <source/>Stem Cells Transl Med. <year>2012</year>; <volume>1</volume>: <fpage>83</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">23197756</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0051">
<label>51</label>
<mixed-citation id="jcmm12839-cit-0051" publication-type="journal">
<string-name>
<surname>Amabile</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Meissner</surname>
<given-names>A</given-names>
</string-name>. <article-title>Induced pluripotent stem cells: current progress and potential for regenerative medicine</article-title>. <source/>Trends Mol Med. <year>2009</year>; <volume>15</volume>: <fpage>59</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">19162546</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0052">
<label>52</label>
<mixed-citation id="jcmm12839-cit-0052" publication-type="journal">
<string-name>
<surname>Hu</surname>
<given-names>B‐Y</given-names>
</string-name>, <string-name>
<surname>Weick</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency</article-title>. <source/>Proc Natl Acad Sci USA. <year>2010</year>; <volume>107</volume>: <fpage>4335</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">20160098</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0053">
<label>53</label>
<mixed-citation id="jcmm12839-cit-0053" publication-type="journal">
<string-name>
<surname>Okamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Induction of retinal pigment epithelial cells from monkey iPS cells</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2011</year>; <volume>52</volume>: <fpage>8785</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">21896853</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0054">
<label>54</label>
<mixed-citation id="jcmm12839-cit-0054" publication-type="journal">
<string-name>
<surname>Hoekstra</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Wilde</surname>
<given-names>AAM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias</article-title>. <source/>Front Physiol. <year>2012</year>; <volume>3</volume>: <fpage>346</fpage>.<pub-id pub-id-type="pmid">23015789</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0055">
<label>55</label>
<mixed-citation id="jcmm12839-cit-0055" publication-type="journal">
<string-name>
<surname>Elefanty</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Stanley</surname>
<given-names>EG</given-names>
</string-name>. <article-title>Efficient generation of adipocytes in a dish</article-title>. <source/>Nat Cell Biol. <year>2012</year>; <volume>14</volume>: <fpage>126</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22298041</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0056">
<label>56</label>
<mixed-citation id="jcmm12839-cit-0056" publication-type="journal">
<string-name>
<surname>Phillips</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Kuznetsov</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Cherman</surname>
<given-names>N</given-names>
</string-name>, <italic>et al</italic>
<article-title>Directed differentiation of human induced pluripotent stem cells toward bone and cartilage: <italic>in vitro versus in vivo</italic> assays</article-title>. <source/>Stem Cells Transl Med. <year>2014</year>; <volume>3</volume>: <fpage>867</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">24855277</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0057">
<label>57</label>
<mixed-citation id="jcmm12839-cit-0057" publication-type="journal">
<string-name>
<surname>Wei</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Chondrogenic differentiation of induced pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix</article-title>. <source/>Eur. Cell. Mater. <year>2012</year>; <volume>23</volume>: <fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">22241609</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0058">
<label>58</label>
<mixed-citation id="jcmm12839-cit-0058" publication-type="journal">
<string-name>
<surname>Lian</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice</article-title>. <source/>Circulation. <year>2010</year>; <volume>121</volume>: <fpage>1113</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">20176987</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0059">
<label>59</label>
<mixed-citation id="jcmm12839-cit-0059" publication-type="journal">
<string-name>
<surname>Suzuki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yamazaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation</article-title>. <source/>Mol Ther. <year>2013</year>; <volume>21</volume>: <fpage>1424</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">23670574</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0060">
<label>60</label>
<mixed-citation id="jcmm12839-cit-0060" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>C‐J</given-names>
</string-name>, <string-name>
<surname>Mitra</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Koya</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Production of embryonic and fetal‐like red blood cells from human induced pluripotent stem cells</article-title>. <source/>PLoS ONE. <year>2011</year>; <volume>6</volume>: <fpage>e25761</fpage>.<pub-id pub-id-type="pmid">22022444</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0061">
<label>61</label>
<mixed-citation id="jcmm12839-cit-0061" publication-type="journal">
<string-name>
<surname>Takayama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Transient activation of c‐MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells</article-title>. <source/>J Exp Med. <year>2010</year>; <volume>207</volume>: <fpage>2817</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">21098095</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0062">
<label>62</label>
<mixed-citation id="jcmm12839-cit-0062" publication-type="journal">
<string-name>
<surname>Adams</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cloutier</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Functional vascular endothelium derived from human induced pluripotent stem cells</article-title>. <source/>Stem Cell Reports. <year>2013</year>; <volume>1</volume>: <fpage>105</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">24052946</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0063">
<label>63</label>
<mixed-citation id="jcmm12839-cit-0063" publication-type="journal">
<string-name>
<surname>Sweeney</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Merling</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>U</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of functionally mature neutrophils from induced pluripotent stem cells</article-title>. <source/>Methods Mol Biol. <year>2014</year>; <volume>1124</volume>: <fpage>189</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">24504953</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0064">
<label>64</label>
<mixed-citation id="jcmm12839-cit-0064" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>SXL</given-names>
</string-name>, <string-name>
<surname>Islam</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficient generation of lung and airway epithelial cells from human pluripotent stem cells</article-title>. <source/>Nat Biotechnol. <year>2014</year>; <volume>32</volume>: <fpage>84</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">24291815</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0065">
<label>65</label>
<mixed-citation id="jcmm12839-cit-0065" publication-type="journal">
<string-name>
<surname>Araoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mae</surname>
<given-names>S‐I</given-names>
</string-name>, <string-name>
<surname>Kurose</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule‐based differentiation methods</article-title>. <source/>PLoS ONE. <year>2014</year>; <volume>9</volume>: <fpage>e84881</fpage>.<pub-id pub-id-type="pmid">24454758</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0066">
<label>66</label>
<mixed-citation id="jcmm12839-cit-0066" publication-type="journal">
<string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Burrows</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells</article-title>. <source/>Nat Commun. <year>2014</year>; <volume>5</volume>: <fpage>3071</fpage>.<pub-id pub-id-type="pmid">24468981</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0067">
<label>67</label>
<mixed-citation id="jcmm12839-cit-0067" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>Y‐F</given-names>
</string-name>, <string-name>
<surname>Tseng</surname>
<given-names>C‐Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H‐W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Rapid generation of mature hepatocyte‐like cells from human induced pluripotent stem cells by an efficient three‐step protocol</article-title>. <source/>Hepatology. <year>2012</year>; <volume>55</volume>: <fpage>1193</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">22095466</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0068">
<label>68</label>
<mixed-citation id="jcmm12839-cit-0068" publication-type="journal">
<string-name>
<surname>Xia</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nivet</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sancho‐Martinez</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor‐like cells</article-title>. <source/>Nat Cell Biol. <year>2013</year>; <volume>15</volume>: <fpage>1507</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">24240476</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0069">
<label>69</label>
<mixed-citation id="jcmm12839-cit-0069" publication-type="journal">
<string-name>
<surname>Takasato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Er</surname>
<given-names>PX</given-names>
</string-name>, <string-name>
<surname>Becroft</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Directing human embryonic stem cell differentiation towards a renal lineage generates a self‐organizing kidney</article-title>. <source/>Nat Cell Biol. <year>2014</year>; <volume>16</volume>: <fpage>118</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">24335651</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0070">
<label>70</label>
<mixed-citation id="jcmm12839-cit-0070" publication-type="journal">
<string-name>
<surname>Hua</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>iPSC‐derived β cells model diabetes due to glucokinase deficiency</article-title>. <source/>J. Clin. Invest. <year>2013</year>; <volume>123</volume>: <fpage>3146</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">23778137</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0071">
<label>71</label>
<mixed-citation id="jcmm12839-cit-0071" publication-type="journal">
<string-name>
<surname>Panula</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Medrano</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Kee</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human germ cell differentiation from fetal‐ and adult‐derived induced pluripotent stem cells</article-title>. <source/>Hum Mol Genet. <year>2011</year>; <volume>20</volume>: <fpage>752</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">21131292</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0072">
<label>72</label>
<mixed-citation id="jcmm12839-cit-0072" publication-type="journal">
<string-name>
<surname>Irie</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Weinberger</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>WWC</given-names>
</string-name>, <italic>et al</italic>
<article-title>SOX17 is a critical specifier of human primordial germ cell fate</article-title>. <source/>Cell. <year>2015</year>; <volume>160</volume>: <fpage>253</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">25543152</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0073">
<label>73</label>
<mixed-citation id="jcmm12839-cit-0073" publication-type="journal">
<string-name>
<surname>Urbach</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bar‐Nur</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Daley</surname>
<given-names>GQ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells</article-title>. <source/>Cell Stem Cell. <year>2010</year>; <volume>6</volume>: <fpage>407</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">20452313</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0074">
<label>74</label>
<mixed-citation id="jcmm12839-cit-0074" publication-type="journal">
<string-name>
<surname>Sheridan</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Theriault</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Reis</surname>
<given-names>SA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome</article-title>. <source/>PLoS ONE. <year>2011</year>; <volume>6</volume>: <fpage>e26203</fpage>.<pub-id pub-id-type="pmid">22022567</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0075">
<label>75</label>
<mixed-citation id="jcmm12839-cit-0075" publication-type="journal">
<string-name>
<surname>Marchetto</surname>
<given-names>MCN</given-names>
</string-name>, <string-name>
<surname>Carromeu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Acab</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells</article-title>. <source/>Cell. <year>2010</year>; <volume>143</volume>: <fpage>527</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">21074045</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0076">
<label>76</label>
<mixed-citation id="jcmm12839-cit-0076" publication-type="journal">
<string-name>
<surname>Chamberlain</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>P‐F</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>KY</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader‐Willi syndromes</article-title>. <source/>Proc Natl Acad Sci USA. <year>2010</year>; <volume>107</volume>: <fpage>17668</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">20876107</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0077">
<label>77</label>
<mixed-citation id="jcmm12839-cit-0077" publication-type="journal">
<string-name>
<surname>Paşca</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Portmann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Voineagu</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Using iPSC‐derived neurons to uncover cellular phenotypes associated with Timothy syndrome</article-title>. <source/>Nat Med. <year>2011</year>; <volume>17</volume>: <fpage>1657</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">22120178</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0078">
<label>78</label>
<mixed-citation id="jcmm12839-cit-0078" publication-type="journal">
<string-name>
<surname>Lancaster</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Renner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>C‐A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Cerebral organoids model human brain development and microcephaly</article-title>. <source/>Nature. <year>2013</year>; <volume>501</volume>: <fpage>373</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23995685</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0079">
<label>79</label>
<mixed-citation id="jcmm12839-cit-0079" publication-type="journal">
<string-name>
<surname>Havlicek</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kohl</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Mishra</surname>
<given-names>HK</given-names>
</string-name>, <italic>et al</italic>
<article-title>Gene dosage dependent rescue of HSP neurite defects in SPG4 patients’ neurons</article-title>. <source/>Hum Mol Genet. <year>2014</year>; <volume>23</volume>: <fpage>2527</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">24381312</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0080">
<label>80</label>
<mixed-citation id="jcmm12839-cit-0080" publication-type="journal">
<string-name>
<surname>Luo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>B</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of induced pluripotent stem cells from skin fibroblasts of a patient with olivopontocerebellar atrophy</article-title>. <source/>Tohoku J Exp Med. <year>2012</year>; <volume>226</volume>: <fpage>151</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">22301348</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0081">
<label>81</label>
<mixed-citation id="jcmm12839-cit-0081" publication-type="journal">
<string-name>
<surname>Shimojima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Imai</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Reduced PLP1 expression in induced pluripotent stem cells derived from a Pelizaeus‐Merzbacher disease patient with a partial PLP1 duplication</article-title>. <source/>J Hum Genet. <year>2012</year>; <volume>57</volume>: <fpage>580</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">22695888</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0082">
<label>82</label>
<mixed-citation id="jcmm12839-cit-0082" publication-type="journal">
<string-name>
<surname>Folmes</surname>
<given-names>CDL</given-names>
</string-name>, <string-name>
<surname>Martinez‐Fernandez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Perales‐Clemente</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>Disease‐causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS</article-title>. <source/>Stem Cells. <year>2013</year>; <volume>31</volume>: <fpage>1298</fpage>–<lpage>308</lpage>.<pub-id pub-id-type="pmid">23553816</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0083">
<label>83</label>
<mixed-citation id="jcmm12839-cit-0083" publication-type="journal">
<string-name>
<surname>Lian</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Lye</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Suan Yeo</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Derivation of clinically compliant MSCs from CD105<sup>+</sup>, CD24<sup>−</sup> differentiated human ESCs</article-title>. <source/>Stem Cells. <year>2007</year>; <volume>25</volume>: <fpage>425</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">17053208</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0084">
<label>84</label>
<mixed-citation id="jcmm12839-cit-0084" publication-type="journal">
<string-name>
<surname>Warren</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Manos</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Ahfeldt</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA</article-title>. <source/>Cell Stem Cell. <year>2010</year>; <volume>7</volume>: <fpage>618</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">20888316</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0085">
<label>85</label>
<mixed-citation id="jcmm12839-cit-0085" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>C‐H</given-names>
</string-name>, <string-name>
<surname>Moon</surname>
<given-names>J‐I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins</article-title>. <source/>Cell Stem Cell. <year>2009</year>; <volume>4</volume>: <fpage>472</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">19481515</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0086">
<label>86</label>
<mixed-citation id="jcmm12839-cit-0086" publication-type="journal">
<string-name>
<surname>Si‐Tayeb</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Noto</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Sepac</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors</article-title>. <source/>BMC Dev Biol. <year>2010</year>; <volume>10</volume>: <fpage>81</fpage>.<pub-id pub-id-type="pmid">20682060</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0087">
<label>87</label>
<mixed-citation id="jcmm12839-cit-0087" publication-type="journal">
<string-name>
<surname>Kawagoe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Otaka</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp)</article-title>. <source/>Mol Genet Metab. <year>2013</year>; <volume>109</volume>: <fpage>386</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23810832</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0088">
<label>88</label>
<mixed-citation id="jcmm12839-cit-0088" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>I‐P</given-names>
</string-name>, <string-name>
<surname>Fukuda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fusaki</surname>
<given-names>N</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell reprogramming by integration‐free sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia</article-title>. <source/>Cell. Reprogram. <year>2013</year>; <volume>15</volume>: <fpage>503</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">24219578</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0089">
<label>89</label>
<mixed-citation id="jcmm12839-cit-0089" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lian</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects</article-title>. <source/>Cell Stem Cell. <year>2011</year>; <volume>8</volume>: <fpage>31</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">21185252</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0090">
<label>90</label>
<mixed-citation id="jcmm12839-cit-0090" publication-type="journal">
<string-name>
<surname>Guzzo</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>R‐H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficient differentiation of human iPSC‐derived mesenchymal stem cells to chondroprogenitor cells</article-title>. <source/>J Cell Biochem. <year>2013</year>; <volume>114</volume>: <fpage>480</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">22961870</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0091">
<label>91</label>
<mixed-citation id="jcmm12839-cit-0091" publication-type="journal">
<string-name>
<surname>Villa‐Diaz</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates</article-title>. <source/>Stem Cells. <year>2012</year>; <volume>30</volume>: <fpage>1174</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">22415987</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0092">
<label>92</label>
<mixed-citation id="jcmm12839-cit-0092" publication-type="journal">
<string-name>
<surname>Wei</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Manasi</surname>
</string-name>, <italic>et al</italic>
<article-title>One‐step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells</article-title>. <source/>Stem Cell Res. <year>2012</year>; <volume>9</volume>: <fpage>87</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">22683798</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0093">
<label>93</label>
<mixed-citation id="jcmm12839-cit-0093" publication-type="journal">
<string-name>
<surname>Eberle</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Moslem</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Henschler</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Engineered MSCs from patient‐specific iPS cells</article-title>. <source/>Adv Biochem Eng Biotechnol. <year>2013</year>; <volume>130</volume>: <fpage>1</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">22915200</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0094">
<label>94</label>
<mixed-citation id="jcmm12839-cit-0094" publication-type="journal">
<string-name>
<surname>Meng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>R‐J</given-names>
</string-name>, <string-name>
<surname>Baylink</surname>
<given-names>DJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Rapid and efficient reprogramming of human fetal and adult blood CD34<sup>+</sup> cells into mesenchymal stem cells with a single factor</article-title>. <source/>Cell Res. <year>2013</year>; <volume>23</volume>: <fpage>658</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">23478301</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0095">
<label>95</label>
<mixed-citation id="jcmm12839-cit-0095" publication-type="journal">
<string-name>
<surname>TheinHan</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell‐derived mesenchymal stem cell seeding on biofunctionalized calcium phosphate cements</article-title>. <source/>Bone Res. <year>2013</year>; <volume>4</volume>: <fpage>371</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">24839581</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0096">
<label>96</label>
<mixed-citation id="jcmm12839-cit-0096" publication-type="journal">
<string-name>
<surname>Houlihan</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Mabuchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Morikawa</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Isolation of mouse mesenchymal stem cells on the basis of expression of Sca‐1 and PDGFR‐α</article-title>. <source/>Nat Protoc. <year>2012</year>; <volume>7</volume>: <fpage>2103</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">23154782</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0097">
<label>97</label>
<mixed-citation id="jcmm12839-cit-0097" publication-type="journal">
<string-name>
<surname>Hare</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fishman</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Gerstenblith</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Comparison of allogeneic <italic>vs</italic> autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial</article-title>. <source/>JAMA. <year>2012</year>; <volume>308</volume>: <fpage>2369</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">23117550</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0098">
<label>98</label>
<mixed-citation id="jcmm12839-cit-0098" publication-type="journal">
<string-name>
<surname>Chou</surname>
<given-names>S‐H</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>S‐Z</given-names>
</string-name>, <string-name>
<surname>Day</surname>
<given-names>CH</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cell insights: prospects in hematological transplantation</article-title>. <source/>Cell Transplant. <year>2013</year>; <volume>22</volume>: <fpage>711</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23190451</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0099">
<label>99</label>
<mixed-citation id="jcmm12839-cit-0099" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Improved cell survival and paracrine capacity of human embryonic stem cell‐derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension</article-title>. <source/>Cell Transplant. <year>2012</year>; <volume>21</volume>: <fpage>2225</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">22776744</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0100">
<label>100</label>
<mixed-citation id="jcmm12839-cit-0100" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>. <article-title>iPSC‐derived mesenchymal stem cells from blood cells as a new source for disc repair</article-title>. <source/>Glob. Spine J. <year>2014</year>; <volume>04</volume>: <fpage>po.073</fpage>.</mixed-citation>
</ref>
<ref id="jcmm12839-bib-0101">
<label>101</label>
<mixed-citation id="jcmm12839-cit-0101" publication-type="journal">
<string-name>
<surname>Shao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>MK</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent mesenchymal stromal cell clones retain donor‐derived differences in DNA methylation profiles</article-title>. <source/>Mol Ther. <year>2013</year>; <volume>21</volume>: <fpage>240</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">23032973</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0102">
<label>102</label>
<mixed-citation id="jcmm12839-cit-0102" publication-type="journal">
<string-name>
<surname>Frobel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hemeda</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lenz</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells</article-title>. <source/>Stem Cell Reports. <year>2014</year>; <volume>3</volume>: <fpage>414</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">25241740</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0103">
<label>103</label>
<mixed-citation id="jcmm12839-cit-0103" publication-type="journal">
<string-name>
<surname>Boyd</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Robbins</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Dhara</surname>
<given-names>SK</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human embryonic stem cell‐derived mesoderm‐like epithelium transitions to mesenchymal progenitor cells</article-title>. <source/>Tissue Eng Part A. <year>2009</year>; <volume>15</volume>: <fpage>1897</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">19196144</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0104">
<label>104</label>
<mixed-citation id="jcmm12839-cit-0104" publication-type="journal">
<string-name>
<surname>Bartholomew</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sturgeon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Siatskas</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells suppress lymphocyte proliferation <italic>in vitro</italic> and prolong skin graft survival <italic>in vivo</italic>
</article-title>. <source/>Exp Hematol. <year>2002</year>; <volume>30</volume>: <fpage>42</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">11823036</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0105">
<label>105</label>
<mixed-citation id="jcmm12839-cit-0105" publication-type="journal">
<string-name>
<surname>Koç</surname>
<given-names>ON</given-names>
</string-name>, <string-name>
<surname>Gerson</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>BW</given-names>
</string-name>, <italic>et al</italic>
<article-title>Rapid hematopoietic recovery after coinfusion of autologous‐blood stem cells and culture‐expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high‐dose chemotherapy</article-title>. <source/>J Clin Oncol. <year>2000</year>; <volume>18</volume>: <fpage>307</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">10637244</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0106">
<label>106</label>
<mixed-citation id="jcmm12839-cit-0106" publication-type="journal">
<string-name>
<surname>Ringdén</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Uzunel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rasmusson</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cells for treatment of therapy‐resistant graft‐versus‐host disease</article-title>. <source/>Transplantation. <year>2006</year>; <volume>81</volume>: <fpage>1390</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">16732175</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0107">
<label>107</label>
<mixed-citation id="jcmm12839-cit-0107" publication-type="journal">
<string-name>
<surname>Kroemer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Edtinger</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>XC</given-names>
</string-name>. <article-title>The innate natural killer cells in transplant rejection and tolerance induction</article-title>. <source/>Curr. Opin. Organ Transplant. <year>2008</year>; <volume>13</volume>: <fpage>339</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">18685327</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0108">
<label>108</label>
<mixed-citation id="jcmm12839-cit-0108" publication-type="journal">
<string-name>
<surname>Ljunggren</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Kärre</surname>
<given-names>K</given-names>
</string-name>. <article-title>In search of the “missing self”: MHC molecules and NK cell recognition</article-title>. <source/>Immunol Today. <year>1990</year>; <volume>11</volume>: <fpage>237</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">2201309</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0109">
<label>109</label>
<mixed-citation id="jcmm12839-cit-0109" publication-type="journal">
<string-name>
<surname>Yang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Aprecio</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>X</given-names>
</string-name>, <italic>et al</italic>
<article-title>Therapeutic effect of TSG‐6 engineered iPSC‐derived MSCs on experimental periodontitis in rats: a pilot study</article-title>. <source/>PLoS ONE. <year>2014</year>; <volume>9</volume>: <fpage>e100285</fpage>.<pub-id pub-id-type="pmid">24979372</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0110">
<label>110</label>
<mixed-citation id="jcmm12839-cit-0110" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>S‐W</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chae</surname>
<given-names>G‐T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Successful stem cell therapy using umbilical cord blood‐derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model</article-title>. <source/>Stem Cells. <year>2006</year>; <volume>24</volume>: <fpage>1620</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">16497946</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0111">
<label>111</label>
<mixed-citation id="jcmm12839-cit-0111" publication-type="journal">
<string-name>
<surname>Trivedi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tray</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later</article-title>. <source/>Stem Cells Dev. <year>2010</year>; <volume>19</volume>: <fpage>1109</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">20092388</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0112">
<label>112</label>
<mixed-citation id="jcmm12839-cit-0112" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>G‐H</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modelling Fanconi anemia pathogenesis and therapeutics using integration‐free patient‐derived iPSCs</article-title>. <source/>Nat Commun. <year>2014</year>; <volume>5</volume>: <fpage>4330</fpage>.<pub-id pub-id-type="pmid">24999918</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0113">
<label>113</label>
<mixed-citation id="jcmm12839-cit-0113" publication-type="journal">
<string-name>
<surname>Urbach</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bar‐Nur</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Daley</surname>
<given-names>GQ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells</article-title>. <source/>Cell Stem Cell. <year>2010</year>; <volume>6</volume>: <fpage>407</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">20452313</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0114">
<label>114</label>
<mixed-citation id="jcmm12839-cit-0114" publication-type="journal">
<string-name>
<surname>Stricker</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Feber</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Engström</surname>
<given-names>PG</given-names>
</string-name>, <italic>et al</italic>
<article-title>Widespread resetting of DNA methylation in glioblastoma‐initiating cells suppresses malignant cellular behavior in a lineage‐dependent manner</article-title>. <source/>Genes Dev. <year>2013</year>; <volume>27</volume>: <fpage>654</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">23512659</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0115">
<label>115</label>
<mixed-citation id="jcmm12839-cit-0115" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>X‐M</given-names>
</string-name>, <string-name>
<surname>Yik</surname>
<given-names>WY</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesis</article-title>. <source/>Stem Cell Res Ther. <year>2012</year>; <volume>3</volume>: <fpage>39</fpage>.<pub-id pub-id-type="pmid">23036268</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0116">
<label>116</label>
<mixed-citation id="jcmm12839-cit-0116" publication-type="journal">
<string-name>
<surname>Song</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Herszfeld</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis</article-title>. <source/>Stem Cell Res. <year>2012</year>; <volume>8</volume>: <fpage>259</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">22265745</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0117">
<label>117</label>
<mixed-citation id="jcmm12839-cit-0117" publication-type="journal">
<string-name>
<surname>DeRosa</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Van Baaren</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Dubey</surname>
<given-names>GK</given-names>
</string-name>, <italic>et al</italic>
<article-title>Derivation of autism spectrum disorder‐specific induced pluripotent stem cells from peripheral blood mononuclear cells</article-title>. <source/>Neurosci Lett. <year>2012</year>; <volume>516</volume>: <fpage>9</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">22405972</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0118">
<label>118</label>
<mixed-citation id="jcmm12839-cit-0118" publication-type="journal">
<string-name>
<surname>Tilgner</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Neganova</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Singhapol</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Brief report: a human induced pluripotent stem cell model of cernunnos deficiency reveals an important role for XLF in the survival of the primitive hematopoietic progenitors</article-title>. <source/>Stem Cells. <year>2013</year>; <volume>31</volume>: <fpage>2015</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">23818183</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0119">
<label>119</label>
<mixed-citation id="jcmm12839-cit-0119" publication-type="journal">
<string-name>
<surname>Adamo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Atashpaz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Germain</surname>
<given-names>P‐L</given-names>
</string-name>, <italic>et al</italic>
<article-title>7q11.23 dosage‐dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease‐relevant lineages</article-title>. <source/>Nat Genet. <year>2014</year>; <volume>47</volume>: <fpage>132</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">25501393</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0120">
<label>120</label>
<mixed-citation id="jcmm12839-cit-0120" publication-type="journal">
<string-name>
<surname>Israel</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Bardy</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells</article-title>. <source/>Nature. <year>2012</year>; <volume>482</volume>: <fpage>216</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">22278060</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0121">
<label>121</label>
<mixed-citation id="jcmm12839-cit-0121" publication-type="journal">
<string-name>
<surname>Yagi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Okada</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling familial Alzheimer's disease with induced pluripotent stem cells</article-title>. <source/>Hum Mol Genet. <year>2011</year>; <volume>20</volume>: <fpage>4530</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21900357</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0122">
<label>122</label>
<mixed-citation id="jcmm12839-cit-0122" publication-type="journal">
<string-name>
<surname>Yahata</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Asai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitaoka</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Anti‐Aβ drug screening platform using human iPS cell‐derived neurons for the treatment of Alzheimer's disease</article-title>. <source/>PLoS ONE. <year>2011</year>; <volume>6</volume>: <fpage>e25788</fpage>.<pub-id pub-id-type="pmid">21984949</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0123">
<label>123</label>
<mixed-citation id="jcmm12839-cit-0123" publication-type="journal">
<string-name>
<surname>Brennand</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Simone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jou</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modelling schizophrenia using human induced pluripotent stem cells</article-title>. <source/>Nature. <year>2011</year>; <volume>473</volume>: <fpage>221</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">21490598</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0124">
<label>124</label>
<mixed-citation id="jcmm12839-cit-0124" publication-type="journal">
<string-name>
<surname>Ebert</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rose</surname>
<given-names>FF</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells from a spinal muscular atrophy patient</article-title>. <source/>Nature. <year>2009</year>; <volume>457</volume>: <fpage>277</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">19098894</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0125">
<label>125</label>
<mixed-citation id="jcmm12839-cit-0125" publication-type="journal">
<string-name>
<surname>Park</surname>
<given-names>I‐H</given-names>
</string-name>, <string-name>
<surname>Arora</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Huo</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Disease‐specific induced pluripotent stem cells</article-title>. <source/>Cell. <year>2008</year>; <volume>134</volume>: <fpage>877</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">18691744</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0126">
<label>126</label>
<mixed-citation id="jcmm12839-cit-0126" publication-type="journal">
<string-name>
<surname>Devine</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ryten</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vodicka</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>Parkinson's disease induced pluripotent stem cells with triplication of the α‐synuclein locus</article-title>. <source/>Nat Commun. <year>2011</year>; <volume>2</volume>: <fpage>440</fpage>.<pub-id pub-id-type="pmid">21863007</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0127">
<label>127</label>
<mixed-citation id="jcmm12839-cit-0127" publication-type="journal">
<string-name>
<surname>Soldner</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hockemeyer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Beard</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Parkinson's disease patient‐derived induced pluripotent stem cells free of viral reprogramming factors</article-title>. <source/>Cell. <year>2009</year>; <volume>136</volume>: <fpage>964</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">19269371</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0128">
<label>128</label>
<mixed-citation id="jcmm12839-cit-0128" publication-type="journal">
<string-name>
<surname>An</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells</article-title>. <source/>Cell Stem Cell. <year>2012</year>; <volume>11</volume>: <fpage>253</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">22748967</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0129">
<label>129</label>
<mixed-citation id="jcmm12839-cit-0129" publication-type="journal">
<string-name>
<surname>Dimos</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Rodolfa</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Niakan</surname>
<given-names>KK</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons</article-title>. <source/>Science. <year>2008</year>; <volume>321</volume>: <fpage>1218</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">18669821</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0130">
<label>130</label>
<mixed-citation id="jcmm12839-cit-0130" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Papapetrou</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modelling pathogenesis and treatment of familial dysautonomia using patient‐specific iPSCs</article-title>. <source/>Nature. <year>2009</year>; <volume>461</volume>: <fpage>402</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">19693009</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0131">
<label>131</label>
<mixed-citation id="jcmm12839-cit-0131" publication-type="journal">
<string-name>
<surname>Jang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>H‐C</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H‐S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell models from X‐linked adrenoleukodystrophy patients</article-title>. <source/>Ann Neurol. <year>2011</year>; <volume>70</volume>: <fpage>402</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21721033</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0132">
<label>132</label>
<mixed-citation id="jcmm12839-cit-0132" publication-type="journal">
<string-name>
<surname>Koch</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Breuer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Peitz</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Excitation‐induced ataxin‐3 aggregation in neurons from patients with Machado‐Joseph disease</article-title>. <source/>Nature. <year>2011</year>; <volume>480</volume>: <fpage>543</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">22113611</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0133">
<label>133</label>
<mixed-citation id="jcmm12839-cit-0133" publication-type="journal">
<string-name>
<surname>Ku</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Soragni</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Campau</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>Friedreich's ataxia induced pluripotent stem cells model intergenerational GAA·TTC triplet repeat instability</article-title>. <source/>Cell Stem Cell. <year>2010</year>; <volume>7</volume>: <fpage>631</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">21040903</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0134">
<label>134</label>
<mixed-citation id="jcmm12839-cit-0134" publication-type="journal">
<string-name>
<surname>Leung</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nah</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Reid</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis</article-title>. <source/>Stem Cell Reports. <year>2013</year>; <volume>1</volume>: <fpage>451</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">24286032</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0135">
<label>135</label>
<mixed-citation id="jcmm12839-cit-0135" publication-type="journal">
<string-name>
<surname>Fong</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Knoferle</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells</article-title>. <source/>Stem Cell Reports. <year>2013</year>; <volume>1</volume>: <fpage>226</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">24319659</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0136">
<label>136</label>
<mixed-citation id="jcmm12839-cit-0136" publication-type="journal">
<string-name>
<surname>Johnson‐Kerner</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Ahmad</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>AG</given-names>
</string-name>, <italic>et al</italic>
<article-title>Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin</article-title>. <source/>Hum Mol Genet. <year>2015</year>; <volume>24</volume>: <fpage>1420</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">25398950</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0137">
<label>137</label>
<mixed-citation id="jcmm12839-cit-0137" publication-type="journal">
<string-name>
<surname>Suh</surname>
<given-names>J‐H</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling of Menkes disease <italic>via</italic> human induced pluripotent stem cells</article-title>. <source/>Biochem Biophys Res Commun. <year>2014</year>; <volume>444</volume>: <fpage>311</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">24468087</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0138">
<label>138</label>
<mixed-citation id="jcmm12839-cit-0138" publication-type="journal">
<string-name>
<surname>Almeida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Coppola</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cell models of progranulin‐deficient frontotemporal dementia uncover specific reversible neuronal defects</article-title>. <source/>Cell Rep. <year>2012</year>; <volume>2</volume>: <fpage>789</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">23063362</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0139">
<label>139</label>
<mixed-citation id="jcmm12839-cit-0139" publication-type="journal">
<string-name>
<surname>Almeida</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gascon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tran</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC‐derived human neurons</article-title>. <source/>Acta Neuropathol. <year>2013</year>; <volume>126</volume>: <fpage>385</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">23836290</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0140">
<label>140</label>
<mixed-citation id="jcmm12839-cit-0140" publication-type="journal">
<string-name>
<surname>Xia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Santostefano</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hamazaki</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of human‐induced pluripotent stem cells to model spinocerebellar ataxia type 2 <italic>in vitro</italic>
</article-title>. <source/>J Mol Neurosci. <year>2013</year>; <volume>51</volume>: <fpage>237</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">23224816</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0141">
<label>141</label>
<mixed-citation id="jcmm12839-cit-0141" publication-type="journal">
<string-name>
<surname>Nayler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gatei</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kozlov</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells from ataxia‐telangiectasia recapitulate the cellular phenotype</article-title>. <source/>Stem Cells Transl Med. <year>2012</year>; <volume>1</volume>: <fpage>523</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">23197857</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0142">
<label>142</label>
<mixed-citation id="jcmm12839-cit-0142" publication-type="journal">
<string-name>
<surname>Higurashi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Uchida</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lossin</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>A human Dravet syndrome model from patient induced pluripotent stem cells</article-title>. <source/>Mol. Brain. <year>2013</year>; <volume>6</volume>: <fpage>19</fpage>.<pub-id pub-id-type="pmid">23639079</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0143">
<label>143</label>
<mixed-citation id="jcmm12839-cit-0143" publication-type="journal">
<string-name>
<surname>Müller</surname>
<given-names>LUW</given-names>
</string-name>, <string-name>
<surname>Milsom</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>CE</given-names>
</string-name>, <italic>et al</italic>
<article-title>Overcoming reprogramming resistance of Fanconi anemia cells</article-title>. <source/>Blood. <year>2012</year>; <volume>119</volume>: <fpage>5449</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">22371882</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0144">
<label>144</label>
<mixed-citation id="jcmm12839-cit-0144" publication-type="journal">
<string-name>
<surname>Sebastiano</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Maeder</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Angstman</surname>
<given-names>JF</given-names>
</string-name>, <italic>et al</italic>
<article-title>
<italic>In situ</italic> genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases</article-title>. <source/>Stem Cells. <year>2011</year>; <volume>29</volume>: <fpage>1717</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">21898685</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0145">
<label>145</label>
<mixed-citation id="jcmm12839-cit-0145" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>C‐G</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Genetic correction of β‐thalassemia patient‐specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice</article-title>. <source/>Cell Res. <year>2012</year>; <volume>22</volume>: <fpage>637</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">22310243</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0146">
<label>146</label>
<mixed-citation id="jcmm12839-cit-0146" publication-type="journal">
<string-name>
<surname>Ye</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mali</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human‐induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders</article-title>. <source/>Blood. <year>2009</year>; <volume>114</volume>: <fpage>5473</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">19797525</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0147">
<label>147</label>
<mixed-citation id="jcmm12839-cit-0147" publication-type="journal">
<string-name>
<surname>Hirata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takayama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jono‐Ohnishi</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL‐mediated signaling</article-title>. <source/>J. Clin. Invest. <year>2013</year>; <volume>123</volume>: <fpage>3802</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">23908116</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0148">
<label>148</label>
<mixed-citation id="jcmm12839-cit-0148" publication-type="journal">
<string-name>
<surname>Yuan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Braunstein</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>Z</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of glycosylphosphatidylinositol anchor protein‐deficient blood cells from human induced pluripotent stem cells</article-title>. <source/>Stem Cells Transl Med. <year>2013</year>; <volume>2</volume>: <fpage>819</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">24113066</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0149">
<label>149</label>
<mixed-citation id="jcmm12839-cit-0149" publication-type="journal">
<string-name>
<surname>Batista</surname>
<given-names>LFZ</given-names>
</string-name>, <string-name>
<surname>Pech</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>FL</given-names>
</string-name>, <italic>et al</italic>
<article-title>Telomere shortening and loss of self‐renewal in dyskeratosis congenita induced pluripotent stem cells</article-title>. <source/>Nature. <year>2011</year>; <volume>474</volume>: <fpage>399</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">21602826</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0150">
<label>150</label>
<mixed-citation id="jcmm12839-cit-0150" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>C‐J</given-names>
</string-name>, <string-name>
<surname>Bouhassira</surname>
<given-names>EE</given-names>
</string-name>. <article-title>Zinc‐finger nuclease‐mediated correction of α‐thalassemia in iPS cells</article-title>. <source/>Blood. <year>2012</year>; <volume>120</volume>: <fpage>3906</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">23002118</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0151">
<label>151</label>
<mixed-citation id="jcmm12839-cit-0151" publication-type="journal">
<string-name>
<surname>Winkler</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Decker</surname>
<given-names>JE</given-names>
</string-name>, <italic>et al</italic>
<article-title>Defective telomere elongation and hematopoiesis from telomerase‐mutant aplastic anemia iPSCs</article-title>. <source/>J. Clin. Invest. <year>2013</year>; <volume>123</volume>: <fpage>1952</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">23585473</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0152">
<label>152</label>
<mixed-citation id="jcmm12839-cit-0152" publication-type="journal">
<string-name>
<surname>Saliba</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hamidi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lenglet</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients</article-title>. <source/>PLoS ONE. <year>2013</year>; <volume>8</volume>: <fpage>e74257</fpage>.<pub-id pub-id-type="pmid">24066127</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0153">
<label>153</label>
<mixed-citation id="jcmm12839-cit-0153" publication-type="journal">
<string-name>
<surname>Kumano</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Arai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hosoi</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples</article-title>. <source/>Blood. <year>2012</year>; <volume>119</volume>: <fpage>6234</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">22592606</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0154">
<label>154</label>
<mixed-citation id="jcmm12839-cit-0154" publication-type="journal">
<string-name>
<surname>Gandre‐Babbe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Paluru</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Aribeana</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Patient‐derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia</article-title>. <source/>Blood. <year>2013</year>; <volume>121</volume>: <fpage>4925</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23620576</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0155">
<label>155</label>
<mixed-citation id="jcmm12839-cit-0155" publication-type="journal">
<string-name>
<surname>Tanaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yamane</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery</article-title>. <source/>Blood. <year>2012</year>; <volume>120</volume>: <fpage>1299</fpage>–<lpage>308</lpage>.<pub-id pub-id-type="pmid">22723549</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0156">
<label>156</label>
<mixed-citation id="jcmm12839-cit-0156" publication-type="journal">
<string-name>
<surname>Zou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sweeney</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>B‐K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Oxidase‐deficient neutrophils from X‐linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease‐mediated safe harbor targeting</article-title>. <source/>Blood. <year>2011</year>; <volume>117</volume>: <fpage>5561</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">21411759</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0157">
<label>157</label>
<mixed-citation id="jcmm12839-cit-0157" publication-type="journal">
<string-name>
<surname>Morishima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Niwa</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Genetic correction of HAX1 in induced pluripotent stem cells from a patient with severe congenital neutropenia improves defective granulopoiesis</article-title>. <source/>Haematologica. <year>2014</year>; <volume>99</volume>: <fpage>19</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">23975175</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0158">
<label>158</label>
<mixed-citation id="jcmm12839-cit-0158" publication-type="journal">
<string-name>
<surname>Ingrungruanglert</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Amarinthnukrowh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rungsiwiwut</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Wiskott‐Aldrich syndrome iPS cells produce megakaryocytes with defects in cytoskeletal rearrangement and proplatelet formation</article-title>. <source/>Thromb Haemost. <year>2015</year>; <volume>113</volume>: <fpage>792</fpage>–<lpage>805</lpage>.<pub-id pub-id-type="pmid">25518736</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0159">
<label>159</label>
<mixed-citation id="jcmm12839-cit-0159" publication-type="journal">
<string-name>
<surname>Yusa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Rashid</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Strick‐Marchand</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Targeted gene correction of α1‐antitrypsin deficiency in induced pluripotent stem cells</article-title>. <source/>Nature. <year>2011</year>; <volume>478</volume>: <fpage>391</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">21993621</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0160">
<label>160</label>
<mixed-citation id="jcmm12839-cit-0160" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>H‐P</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>P‐H</given-names>
</string-name>, <string-name>
<surname>Hwu</surname>
<given-names>W‐L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human Pompe disease‐induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification</article-title>. <source/>Hum Mol Genet. <year>2011</year>; <volume>20</volume>: <fpage>4851</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">21926084</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0161">
<label>161</label>
<mixed-citation id="jcmm12839-cit-0161" publication-type="journal">
<string-name>
<surname>Cayo</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>DeLaForest</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>JD induced pluripotent stem cell‐derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia</article-title>. <source/>Hepatology. <year>2012</year>; <volume>56</volume>: <fpage>2163</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">22653811</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0162">
<label>162</label>
<mixed-citation id="jcmm12839-cit-0162" publication-type="journal">
<string-name>
<surname>Ghodsizadeh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Taei</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Totonchi</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of liver disease‐specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte‐like cells</article-title>. <source/>Stem Cell Rev. <year>2010</year>; <volume>6</volume>: <fpage>622</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">20821352</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0163">
<label>163</label>
<mixed-citation id="jcmm12839-cit-0163" publication-type="journal">
<string-name>
<surname>Tolar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>I‐H</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)</article-title>. <source/>Blood. <year>2011</year>; <volume>117</volume>: <fpage>839</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">21037085</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0164">
<label>164</label>
<mixed-citation id="jcmm12839-cit-0164" publication-type="journal">
<string-name>
<surname>Lojewski</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Staropoli</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Biswas‐Legrand</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway</article-title>. <source/>Hum Mol Genet. <year>2014</year>; <volume>23</volume>: <fpage>2005</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">24271013</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0165">
<label>165</label>
<mixed-citation id="jcmm12839-cit-0165" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Rescue of ATP7B function in hepatocyte‐like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin</article-title>. <source/>Hum Mol Genet. <year>2011</year>; <volume>20</volume>: <fpage>3176</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">21593220</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0166">
<label>166</label>
<mixed-citation id="jcmm12839-cit-0166" publication-type="journal">
<string-name>
<surname>Fujikura</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sone</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation</article-title>. <source/>Diabetologia. <year>2012</year>; <volume>55</volume>: <fpage>1689</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">22396012</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0167">
<label>167</label>
<mixed-citation id="jcmm12839-cit-0167" publication-type="journal">
<string-name>
<surname>Lemonnier</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Blanchard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Toli</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling neuronal defects associated with a lysosomal disorder using patient‐derived induced pluripotent stem cells</article-title>. <source/>Hum Mol Genet. <year>2011</year>; <volume>20</volume>: <fpage>3653</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">21685203</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0168">
<label>168</label>
<mixed-citation id="jcmm12839-cit-0168" publication-type="journal">
<string-name>
<surname>Moretti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ph</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bellin</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Patient‐specific induced pluripotent stem‐cell models for long‐QT syndrome</article-title>. <source/>N Engl J Med. <year>2010</year>; <volume>363</volume>: <fpage>1397</fpage>–<lpage>409</lpage>.<pub-id pub-id-type="pmid">20660394</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0169">
<label>169</label>
<mixed-citation id="jcmm12839-cit-0169" publication-type="journal">
<string-name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Maizels</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modelling the long QT syndrome with induced pluripotent stem cells</article-title>. <source/>Nature. <year>2011</year>; <volume>471</volume>: <fpage>225</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21240260</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0170">
<label>170</label>
<mixed-citation id="jcmm12839-cit-0170" publication-type="journal">
<string-name>
<surname>Ma</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling type 3 long QT syndrome with cardiomyocytes derived from patient‐specific induced pluripotent stem cells</article-title>. <source/>Int J Cardiol. <year>2013</year>; <volume>168</volume>: <fpage>5277</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">23998552</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0171">
<label>171</label>
<mixed-citation id="jcmm12839-cit-0171" publication-type="journal">
<string-name>
<surname>Ge</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bartulos</surname>
<given-names>O</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells</article-title>. <source/>Circulation. <year>2012</year>; <volume>126</volume>: <fpage>1695</fpage>–<lpage>704</lpage>.<pub-id pub-id-type="pmid">22914687</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0172">
<label>172</label>
<mixed-citation id="jcmm12839-cit-0172" publication-type="journal">
<string-name>
<surname>Tanaka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yuasa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mearini</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Endothelin‐1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy‐induced pluripotent stem cell‐derived cardiomyocytes</article-title>. <source/>J Am Heart Assoc. <year>2014</year>; <volume>3</volume>: <fpage>e001263</fpage>–<lpage>e001263</lpage>.<pub-id pub-id-type="pmid">25389285</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0173">
<label>173</label>
<mixed-citation id="jcmm12839-cit-0173" publication-type="journal">
<string-name>
<surname>Drawnel</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Boccardo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Prummer</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells</article-title>. <source/>Cell Rep. <year>2014</year>; <volume>9</volume>: <fpage>810</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">25437537</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0174">
<label>174</label>
<mixed-citation id="jcmm12839-cit-0174" publication-type="journal">
<string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Habibollah</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tilgner</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS‐derived cardiac myocytes</article-title>. <source/>Stem Cells Transl Med. <year>2014</year>; <volume>3</volume>: <fpage>416</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">24591732</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0175">
<label>175</label>
<mixed-citation id="jcmm12839-cit-0175" publication-type="journal">
<string-name>
<surname>Hitomi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Habu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality</article-title>. <source/>Biochem Biophys Res Commun. <year>2013</year>; <volume>439</volume>: <fpage>419</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">23994138</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0176">
<label>176</label>
<mixed-citation id="jcmm12839-cit-0176" publication-type="journal">
<string-name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Maizels</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling of catecholaminergic polymorphic ventricular tachycardia with patient‐specific human‐induced pluripotent stem cells</article-title>. <source/>J Am Coll Cardiol. <year>2012</year>; <volume>60</volume>: <fpage>990</fpage>–<lpage>1000</lpage>.<pub-id pub-id-type="pmid">22749309</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0177">
<label>177</label>
<mixed-citation id="jcmm12839-cit-0177" publication-type="journal">
<string-name>
<surname>Sun</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yazawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Patient‐specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy</article-title>. <source/>Sci Transl Med. <year>2012</year>; <volume>4</volume>: <fpage>130ra47</fpage>.</mixed-citation>
</ref>
<ref id="jcmm12839-bib-0178">
<label>178</label>
<mixed-citation id="jcmm12839-cit-0178" publication-type="journal">
<string-name>
<surname>Lan</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient‐specific induced pluripotent stem cells</article-title>. <source/>Cell Stem Cell. <year>2013</year>; <volume>12</volume>: <fpage>101</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">23290139</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0179">
<label>179</label>
<mixed-citation id="jcmm12839-cit-0179" publication-type="journal">
<string-name>
<surname>Pessach</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Ordovas‐Montanes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>S‐Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies</article-title>. <source/>J. Allergy Clin. Immunol. <year>2011</year>; <volume>127</volume>: <fpage>1400</fpage>–<lpage>7.e4</lpage>.<pub-id pub-id-type="pmid">21185069</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0180">
<label>180</label>
<mixed-citation id="jcmm12839-cit-0180" publication-type="journal">
<string-name>
<surname>Deyle</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Normal collagen and bone production by gene‐targeted human osteogenesis imperfecta iPSCs</article-title>. <source/>Mol Ther. <year>2012</year>; <volume>20</volume>: <fpage>204</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">22031238</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0181">
<label>181</label>
<mixed-citation id="jcmm12839-cit-0181" publication-type="journal">
<string-name>
<surname>Yamashita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morioka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kishi</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Statin treatment rescues FGFR3 skeletal dysplasia phenotypes</article-title>. <source/>Nature. <year>2014</year>; <volume>513</volume>: <fpage>507</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">25231866</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0182">
<label>182</label>
<mixed-citation id="jcmm12839-cit-0182" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>G‐H</given-names>
</string-name>, <string-name>
<surname>Barkho</surname>
<given-names>BZ</given-names>
</string-name>, <string-name>
<surname>Ruiz</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Recapitulation of premature ageing with iPSCs from Hutchinson‐Gilford progeria syndrome</article-title>. <source/>Nature. <year>2011</year>; <volume>472</volume>: <fpage>221</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">21346760</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0183">
<label>183</label>
<mixed-citation id="jcmm12839-cit-0183" publication-type="journal">
<string-name>
<surname>Shimamoto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kagawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zensho</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Reprogramming suppresses premature senescence phenotypes of werner syndrome cells and maintains chromosomal stability over long‐term culture</article-title>. <source/>PLoS ONE. <year>2014</year>; <volume>9</volume>: <fpage>e112900</fpage>.<pub-id pub-id-type="pmid">25390333</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0184">
<label>184</label>
<mixed-citation id="jcmm12839-cit-0184" publication-type="journal">
<string-name>
<surname>Snider</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Geng</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Lemmers</surname>
<given-names>RJLF</given-names>
</string-name>, <italic>et al</italic>
<article-title>Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene</article-title>. <source/>PLoS Genet. <year>2010</year>; <volume>6</volume>: <fpage>e1001181</fpage>.<pub-id pub-id-type="pmid">21060811</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0185">
<label>185</label>
<mixed-citation id="jcmm12839-cit-0185" publication-type="journal">
<string-name>
<surname>Tedesco</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Gerli</surname>
<given-names>MFM</given-names>
</string-name>, <string-name>
<surname>Perani</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Transplantation of genetically corrected human iPSC‐derived progenitors in mice with limb‐girdle muscular dystrophy</article-title>. <source/>Sci Transl Med. <year>2012</year>; <volume>4</volume>: <fpage>140ra89</fpage>.</mixed-citation>
</ref>
<ref id="jcmm12839-bib-0186">
<label>186</label>
<mixed-citation id="jcmm12839-cit-0186" publication-type="journal">
<string-name>
<surname>Du</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Campau</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Soragni</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>Length‐dependent CTG·CAG triplet‐repeat expansion in myotonic dystrophy patient‐derived induced pluripotent stem cells</article-title>. <source/>Hum Mol Genet. <year>2013</year>; <volume>22</volume>: <fpage>5276</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">23933738</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0187">
<label>187</label>
<mixed-citation id="jcmm12839-cit-0187" publication-type="journal">
<string-name>
<surname>Quarto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient‐specific induced‐pluripotent stem cells</article-title>. <source/>Proc Natl Acad Sci USA. <year>2012</year>; <volume>109</volume>: <fpage>215</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">22178754</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0188">
<label>188</label>
<mixed-citation id="jcmm12839-cit-0188" publication-type="journal">
<string-name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Schlieve</surname>
<given-names>CR</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation</article-title>. <source/>Orphanet J. Rare Dis. <year>2013</year>; <volume>8</volume>: <fpage>190</fpage>.<pub-id pub-id-type="pmid">24321451</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0189">
<label>189</label>
<mixed-citation id="jcmm12839-cit-0189" publication-type="journal">
<string-name>
<surname>Mou</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sherwood</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of multipotent lung and airway progenitors from mouse ESCs and patient‐specific cystic fibrosis iPSCs</article-title>. <source/>Cell Stem Cell. <year>2012</year>; <volume>10</volume>: <fpage>385</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">22482504</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0190">
<label>190</label>
<mixed-citation id="jcmm12839-cit-0190" publication-type="journal">
<string-name>
<surname>Lachmann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Happle</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ackermann</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis</article-title>. <source/>Am J Respir Crit Care Med. <year>2014</year>; <volume>189</volume>: <fpage>167</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">24279725</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0191">
<label>191</label>
<mixed-citation id="jcmm12839-cit-0191" publication-type="journal">
<string-name>
<surname>Somers</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jean</surname>
<given-names>J‐C</given-names>
</string-name>, <string-name>
<surname>Sommer</surname>
<given-names>CA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Generation of transgene‐free lung disease‐specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette</article-title>. <source/>Stem Cells. <year>2010</year>; <volume>28</volume>: <fpage>1728</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">20715179</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0192">
<label>192</label>
<mixed-citation id="jcmm12839-cit-0192" publication-type="journal">
<string-name>
<surname>Tolar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Riddle</surname>
<given-names>MJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa</article-title>. <source/>J. Invest. Dermatol. <year>2011</year>; <volume>131</volume>: <fpage>848</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">21124339</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0193">
<label>193</label>
<mixed-citation id="jcmm12839-cit-0193" publication-type="journal">
<string-name>
<surname>Tolar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McGrath</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Patient‐specific naturally gene‐reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa</article-title>. <source/>J. Invest. Dermatol. <year>2013</year>; <volume>134</volume>: <fpage>1246</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">24317394</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0194">
<label>194</label>
<mixed-citation id="jcmm12839-cit-0194" publication-type="journal">
<string-name>
<surname>Ross</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Busch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mintz</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>A rare human syndrome provides genetic evidence that WNT signaling is required for reprogramming of fibroblasts to induced pluripotent stem cells</article-title>. <source/>Cell Rep. <year>2014</year>; <volume>9</volume>: <fpage>1770</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">25464842</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0195">
<label>195</label>
<mixed-citation id="jcmm12839-cit-0195" publication-type="journal">
<string-name>
<surname>Mica</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chambers</surname>
<given-names>SM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling neural crest induction, melanocyte specification, and disease‐related pigmentation defects in hESCs and patient‐specific iPSCs</article-title>. <source/>Cell Rep. <year>2013</year>; <volume>3</volume>: <fpage>1140</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">23583175</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0196">
<label>196</label>
<mixed-citation id="jcmm12839-cit-0196" publication-type="journal">
<string-name>
<surname>Soyombo</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kolski</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Analysis of induced pluripotent stem cells from a BRCA1 mutant family</article-title>. <source/>Stem Cell Reports. <year>2013</year>; <volume>1</volume>: <fpage>336</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">24319668</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0197">
<label>197</label>
<mixed-citation id="jcmm12839-cit-0197" publication-type="journal">
<string-name>
<surname>Jin</surname>
<given-names>Z‐B</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osakada</surname>
<given-names>F</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling retinal degeneration using patient‐specific induced pluripotent stem cells</article-title>. <source/>PLoS ONE. <year>2011</year>; <volume>6</volume>: <fpage>e17084</fpage>.<pub-id pub-id-type="pmid">21347327</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0198">
<label>198</label>
<mixed-citation id="jcmm12839-cit-0198" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>W‐H</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>C‐W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Gene therapy in patient‐specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled‐related protein defects</article-title>. <source/>Mol Ther. <year>2014</year>; <volume>22</volume>: <fpage>1688</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">24895994</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0199">
<label>199</label>
<mixed-citation id="jcmm12839-cit-0199" publication-type="journal">
<string-name>
<surname>Howden</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Gore</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <italic>et al</italic>
<article-title>Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy</article-title>. <source/>Proc Natl Acad Sci USA. <year>2011</year>; <volume>108</volume>: <fpage>6537</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">21464322</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0200">
<label>200</label>
<mixed-citation id="jcmm12839-cit-0200" publication-type="journal">
<string-name>
<surname>Singh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Kuai</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration</article-title>. <source/>Hum Mol Genet. <year>2013</year>; <volume>22</volume>: <fpage>593</fpage>–<lpage>607</lpage>.<pub-id pub-id-type="pmid">23139242</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0201">
<label>201</label>
<mixed-citation id="jcmm12839-cit-0201" publication-type="journal">
<string-name>
<surname>Qiu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficient generation of lens progenitor cells from cataract patient‐specific induced pluripotent stem cells</article-title>. <source/>PLoS ONE. <year>2012</year>; <volume>7</volume>: <fpage>e32612</fpage>.<pub-id pub-id-type="pmid">22403680</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0202">
<label>202</label>
<mixed-citation id="jcmm12839-cit-0202" publication-type="journal">
<string-name>
<surname>Shalom‐Feuerstein</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Serror</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Aberdam</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia‐related patients is rescued by the small compound APR‐246/PRIMA‐1MET</article-title>. <source/>Proc Natl Acad Sci USA. <year>2013</year>; <volume>110</volume>: <fpage>2152</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">23355677</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0203">
<label>203</label>
<mixed-citation id="jcmm12839-cit-0203" publication-type="journal">
<string-name>
<surname>Thatava</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>De Lamo</surname>
<given-names>JG</given-names>
</string-name>, <italic>et al</italic>
<article-title>Successful disease‐specific induced pluripotent stem cell generation from patients with kidney transplantation</article-title>. <source/>Stem Cell Res Ther. <year>2011</year>; <volume>2</volume>: <fpage>48</fpage>.<pub-id pub-id-type="pmid">22142803</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0204">
<label>204</label>
<mixed-citation id="jcmm12839-cit-0204" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modeling abnormal early development with induced pluripotent stem cells from aneuploid syndromes</article-title>. <source/>Hum Mol Genet. <year>2012</year>; <volume>21</volume>: <fpage>32</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">21949351</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0205">
<label>205</label>
<mixed-citation id="jcmm12839-cit-0205" publication-type="journal">
<string-name>
<surname>Ma</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Aberrant gene expression profiles in pluripotent stem cells induced from fibroblasts of a Klinefelter syndrome patient</article-title>. <source/>J Biol Chem. <year>2012</year>; <volume>287</volume>: <fpage>38970</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23019320</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0206">
<label>206</label>
<mixed-citation id="jcmm12839-cit-0206" publication-type="journal">
<string-name>
<surname>Nakagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takizawa</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Narita</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Promotion of direct reprogramming by transformation‐deficient Myc</article-title>. <source/>Proc Natl Acad Sci USA. <year>2010</year>; <volume>107</volume>: <fpage>14152</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">20660764</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0207">
<label>207</label>
<mixed-citation id="jcmm12839-cit-0207" publication-type="journal">
<string-name>
<surname>Fang</surname>
<given-names>I‐M</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>C‐M</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>C‐H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Transplantation of induced pluripotent stem cells without C‐Myc attenuates retinal ischemia and reperfusion injury in rats</article-title>. <source/>Exp Eye Res. <year>2013</year>; <volume>113</volume>: <fpage>49</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">23726881</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0208">
<label>208</label>
<mixed-citation id="jcmm12839-cit-0208" publication-type="journal">
<string-name>
<surname>Sidhu</surname>
<given-names>KS</given-names>
</string-name>. <article-title>New approaches for the generation of induced pluripotent stem cells</article-title>. <source/>Expert Opin. Biol. Ther. <year>2011</year>; <volume>11</volume>: <fpage>569</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">21314494</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0209">
<label>209</label>
<mixed-citation id="jcmm12839-cit-0209" publication-type="journal">
<string-name>
<surname>Cho</surname>
<given-names>H‐J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>C‐S</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>
<given-names>Y‐W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Induction of pluripotent stem cells from adult somatic cells by protein‐based reprogramming without genetic manipulation</article-title>. <source/>Blood. <year>2010</year>; <volume>116</volume>: <fpage>386</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">20439621</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0210">
<label>210</label>
<mixed-citation id="jcmm12839-cit-0210" publication-type="journal">
<string-name>
<surname>Sun</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Longaker</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Human iPS cell‐based therapy: considerations before clinical applications</article-title>. <source/>Cell Cycle. <year>2010</year>; <volume>9</volume>: <fpage>880</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">20160515</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0211">
<label>211</label>
<mixed-citation id="jcmm12839-cit-0211" publication-type="journal">
<string-name>
<surname>Okita</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nagata</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</string-name>. <article-title>Immunogenicity of induced pluripotent stem cells</article-title>. <source/>Circ Res. <year>2011</year>; <volume>109</volume>: <fpage>720</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="pmid">21921270</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0212">
<label>212</label>
<mixed-citation id="jcmm12839-cit-0212" publication-type="journal">
<string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Smuga‐Otto</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human induced pluripotent stem cells free of vector and transgene sequences</article-title>. <source/>Science. <year>2009</year>; <volume>324</volume>: <fpage>797</fpage>–<lpage>801</lpage>.<pub-id pub-id-type="pmid">19325077</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0213">
<label>213</label>
<mixed-citation id="jcmm12839-cit-0213" publication-type="journal">
<string-name>
<surname>Condic</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>M</given-names>
</string-name>. <article-title>Regulatory issues for personalized pluripotent cells</article-title>. <source/>Stem Cells. <year>2008</year>; <volume>26</volume>: <fpage>2753</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">18669906</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0214">
<label>214</label>
<mixed-citation id="jcmm12839-cit-0214" publication-type="journal">
<string-name>
<surname>Knoepfler</surname>
<given-names>PS</given-names>
</string-name>. <article-title>Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells</article-title>. <source/>Regen Med. <year>2012</year>; <volume>7</volume>: <fpage>713</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">22830621</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0215">
<label>215</label>
<mixed-citation id="jcmm12839-cit-0215" publication-type="journal">
<string-name>
<surname>Harding</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mirochnitchenko</surname>
<given-names>O</given-names>
</string-name>. <article-title>Preclinical studies for induced pluripotent stem cell‐based therapeutics</article-title>. <source/>J Biol Chem. <year>2014</year>; <volume>289</volume>: <fpage>4585</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">24362021</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0216">
<label>216</label>
<mixed-citation id="jcmm12839-cit-0216" publication-type="journal">
<string-name>
<surname>Takagi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Saiki</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model</article-title>. <source/>J. Clin. Invest. <year>2005</year>; <volume>115</volume>: <fpage>102</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">15630449</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0217">
<label>217</label>
<mixed-citation id="jcmm12839-cit-0217" publication-type="journal">
<string-name>
<surname>Ishii</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yasuchika</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Machimoto</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Transplantation of embryonic stem cell‐derived endodermal cells into mice with induced lethal liver damage</article-title>. <source/>Stem Cells. <year>2007</year>; <volume>25</volume>: <fpage>3252</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">17885077</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0218">
<label>218</label>
<mixed-citation id="jcmm12839-cit-0218" publication-type="journal">
<string-name>
<surname>Leor</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gerecht</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human embryonic stem cell transplantation to repair the infarcted myocardium</article-title>. <source/>Heart. <year>2007</year>; <volume>93</volume>: <fpage>1278</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">17566061</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0219">
<label>219</label>
<mixed-citation id="jcmm12839-cit-0219" publication-type="journal">
<string-name>
<surname>Boyd</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Higashi</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>A comparison of protocols used to generate insulin‐producing cell clusters from mouse embryonic stem cells</article-title>. <source/>Stem Cells. <year>2008</year>; <volume>26</volume>: <fpage>1128</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">18323410</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0220">
<label>220</label>
<mixed-citation id="jcmm12839-cit-0220" publication-type="journal">
<string-name>
<surname>Hou</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <italic>et al</italic>
<article-title>Pluripotent stem cells induced from mouse somatic cells by small‐molecule compounds</article-title>. <source/>Science. <year>2013</year>; <volume>341</volume>: <fpage>651</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">23868920</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0221">
<label>221</label>
<mixed-citation id="jcmm12839-cit-0221" publication-type="journal">
<string-name>
<surname>Hentze</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Graichen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Colman</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cell therapy and the safety of embryonic stem cell‐derived grafts</article-title>. <source/>Trends Biotechnol. <year>2007</year>; <volume>25</volume>: <fpage>24</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">17084475</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0222">
<label>222</label>
<mixed-citation id="jcmm12839-cit-0222" publication-type="journal">
<string-name>
<surname>Halme</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Kessler</surname>
<given-names>DA</given-names>
</string-name>. <article-title>FDA regulation of stem‐cell‐based therapies</article-title>. <source/>N Engl J Med. <year>2006</year>; <volume>355</volume>: <fpage>1730</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">17050899</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0223">
<label>223</label>
<mixed-citation id="jcmm12839-cit-0223" publication-type="journal">
<string-name>
<surname>Rao</surname>
<given-names>M</given-names>
</string-name>. <article-title>Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues</article-title>. <source/>Gene Ther. <year>2008</year>; <volume>15</volume>: <fpage>82</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">18004405</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0224">
<label>224</label>
<mixed-citation id="jcmm12839-cit-0224" publication-type="journal">
<string-name>
<surname>Liao</surname>
<given-names>M‐C</given-names>
</string-name>, <string-name>
<surname>Diaconu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Monecke</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Embryonic stem cell‐derived neural progenitors as non‐tumorigenic source for dopaminergic neurons</article-title>. <source/>World J. Stem Cells. <year>2014</year>; <volume>6</volume>: <fpage>248</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">24772251</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0225">
<label>225</label>
<mixed-citation id="jcmm12839-cit-0225" publication-type="journal">
<string-name>
<surname>Shibata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ageyama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Improved safety of hematopoietic transplantation with monkey embryonic stem cells in the allogeneic setting</article-title>. <source/>Stem Cells. <year>2006</year>; <volume>24</volume>: <fpage>1450</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">16456125</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0226">
<label>226</label>
<mixed-citation id="jcmm12839-cit-0226" publication-type="journal">
<string-name>
<surname>Fujikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>S‐H</given-names>
</string-name>, <string-name>
<surname>Pi</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell‐derived insulin‐producing cells</article-title>. <source/>Am J Pathol. <year>2005</year>; <volume>166</volume>: <fpage>1781</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">15920163</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0227">
<label>227</label>
<mixed-citation id="jcmm12839-cit-0227" publication-type="journal">
<string-name>
<surname>Fair</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Cairns</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Lapaglia</surname>
<given-names>MA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Correction of factor IX deficiency in mice by embryonic stem cells differentiated <italic>in vitro</italic>
</article-title>. <source/>Proc Natl Acad Sci USA. <year>2005</year>; <volume>102</volume>: <fpage>2958</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">15699326</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0228">
<label>228</label>
<mixed-citation id="jcmm12839-cit-0228" publication-type="journal">
<string-name>
<surname>Arnhold</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Semkova</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>Neurally selected embryonic stem cells induce tumor formation after long‐term survival following engraftment into the subretinal space</article-title>. <source/>Invest Ophthalmol Vis Sci. <year>2004</year>; <volume>45</volume>: <fpage>4251</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">15557428</pub-id></mixed-citation>
</ref>
<ref id="jcmm12839-bib-0229">
<label>229</label>
<mixed-citation id="jcmm12839-cit-0229" publication-type="journal">
<string-name>
<surname>Park</surname>
<given-names>I‐H</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>West</surname>
<given-names>JA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Reprogramming of human somatic cells to pluripotency with defined factors</article-title>. <source/>Nature. <year>2008</year>; <volume>451</volume>: <fpage>141</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18157115</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>